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GENERAL INTRODUCTION 
Objectives of dissertation research 
Equine infectious anemia virus (EIAV) is a member of the lentivirus 
subfamily of retroviruses. Like other lentiviruses, EIAV replicates in cells of the 
monocyte/macrophage lineage, has a complex genome, and causes an 
immunopathology [16,34,40,45,77,78,83,99,111]. One of three types of clinical 
disease, acute, chronic, or aclinical, may occur in an EIAV-infected animal 
[40,45,83,111]. Acute disease is characterized by fever, mucosal hemorrhage, 
anemia, edema, and rapid death. Animals which exhibit chronic disease have 
clinical signs similar to the acute form, but they are less severe and occur in a 
cyclic manner. Animals with aclinical disease show no apparent signs of disease, 
but remain infected carriers for life. 
Both viral and host factors are thought to be involved in determining the 
outcome of clinical disease in an EIAV-infected horse. Viral factors include the 
virulence of different isolates, antigenic variation to escape the host immune 
response, sequence heterogeneity in viral regulatory elements, as well as the co­
existence of varying genotypes in vivo [1,5,50,55,56,89,100]. Host factors are not 
as clearly defined, but likely include host immune competence and qualitative 
differences in cellular co-factors involved in viral gene regulation [89]. 
The severity of clinical disease appears to be correlated with the levels of 
virus replication in an infected animal [56]. In addition, the host's ability to 
control virus replication appears to determine its ability to remain free of 
clinical signs of disease [15,56]. Therefore, it is our hypothesis that cellular 
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factors which control the rate of EIAV replication early after infection are 
important determinants in the outcome of clinical disease in an EIAV-infected 
animal. The overall objective of this research was to identify cellular and viral 
factors which regulate EIAV replication in primary equine macrophage cultures 
(HMC). The specific objectives were 1) to examine the variability of EIAV 
replication in primary HMC established from different horses; 2) to determine 
the effects of macrophage activation on EIAV replication; and 3) to examine the 
effects of macrophage activation on specific stages of EIAV replication. 
Dissertation organization 
This dissertation consists of two manuscripts which are preceeded by 
General Introduction and Literature Review sections and followed by General 
Conclusion and Additional Literature Cited sections. The format of each 
manuscript is that of the journal to which it was submitted. Bibliographical 
information corresponding to literature citations which occur in the text of each 
manuscript can be found at the end of that particular chapter. Bibliographical 
information corresponding to citations made in the text of the General 
Introduction, Literature Review and General Conclusion sections are located in 
the Additional Literature Cited section. 
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LITERATURE REVIEW 
R e t r o v i r u s e s  
Retroviruses are a family of single-stranded RNA viruses which infect 
mainly vertebrate species, and produce a variety of diseases, such as 
malignancies, wasting diseases, neurological disorders, immunodeficiencies, as 
well as persistent viremia without apparent signs of disease [20-22]. The virion 
structure shared by members of this family is approximately 100 nm in size and 
consists of an inner spherical to conical nucleocapsid surrounded by a 
glycoprotein envelope [21,22]. Also included in the core are several proteins 
which function enzymatically during virus replication: a protease cleaves the 
viral precursor proteins to form the mature structural proteins which make up 
the nucleocapsid; reverse transcriptase, an RNA dependent DNA polymerase, that 
converts the single-stranded RNA genome to double-stranded DNA; and integrase 
which produces the pro virus by covalently joining the viral DNA to cellular DNA. 
The retroviral genome is made up of two identical, positive-sense, linear 
RNA molecules, approximately seven to 10 kb in length, which are capped at the 
5' end and polyadenylated at the 3' end [22]. Structural proteins are encoded in 
the following order: Gag (core proteins), Pol (polymerase), and Env (envelope). 
Both ends of the genome contain sequences of the long terminal repeat (LTR) 
which functions in promotion, enhancement, and regulation of virus 
replication. The genome of certain subfamilies of retroviruses encodes 
additional proteins which function to regulate viral gene expression [22]. 
Replication of all members of the retrovirus family involves a DNA 
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intermediate which is produced by the unique virally encoded enzyme, reverse 
transcriptase [20-22]. After entry of the virion core into the cytoplasm, a double-
stranded DNA molecule is transcribed from the viral RNA template (Figure 1). 
Following reverse transcription, the viral DNA is transported to the cell nucleus 
and integrated into the host genome. All of these early steps in virus replication 
are mediated by virally encoded proteins which are brought into the cell during 
infection, therefore, synthesis of viral proteins is not required to achieve 
proviral integration [22]. The intermediate stages in virus replication of 
transcription and translation involve both viral proteins and host-cell 
machinery. Encapsidation of the genome by viral structural proteins and 
budding through the cell membrane to acquire the viral envelope are late events 
in virus replication. 
Three subfamilies of retroviruses have been described based on 
pathogenicity: Oncovirinae; Spumavirinae; and Lentivirinae [21,22]. 
Oncoviruses are made up of five groups of viruses which produce sarcomas and 
leukemias in a variety of animals. Spumaviruses, or foamy viruses, have been 
isolated from a variety of cells in culture, although, they have not been 
associated with any known diseases. A third retrovirus subfamily, lentiviruses, 
typically induce chronic degenerative diseases which are neurological and/or 
immunological in nature. 
L e n t i v i r u s e s  
The lentivirus subfamily of retroviruses includes the human (HIV), 
simian, and feline immunodeficiency viruses, as well as the prototype visna. 
Figure 1. Overview of retrovirus replication (Taken from Coffin, 1991) 
Adtoiplionto 
•paciteraoaptor 
UanieripUon 
JiMgration 
pmMiruf 
7  
caprine arthritis-encephalitis, and equine infectious anemia viruses (EIAV) [20-
22]. A complex genome organization is one characteristic shared by members of 
this subfamily [83]. In addition to the structural proteins, regulatory proteins, 
such as Tat and Rev, are encoded in their genomes. HIV is the most complex of 
the lentivirus group, and therefore, is used as a model for discussing lentiviral 
replication in this literature review. Encoded in the HIV genome are the 
regulatory proteins Tat, Rev, and Nef, as well as three gene products, Vpr, Vif, 
and Vpu, which influence the efficiency of viral spread [22,25,37,64]. 
Transcription of lentiviruses is mediated by the LTR [21,25,37]. Initiation 
occurs in the 5' LTR which also contains the promoter, cellular protein binding 
sites, and enhancer sequences. The 3' LTR contains transcriptional termination 
signals as well as the signal for 3' polyadenylation. Both constitutive and 
inducible cellular transcription factors are capable of interacting with 
recognition sequences in the 5' HIV LTR [25,37]. Sp-1 and the TATA factor TFIID 
are examples of constitutively expressed factors shown to mediate promoter 
function for cellular and viral genes [47]. The inducible transcription factor NF-
KB is involved in tissue-specific and inducible gene expression in many types of 
human cells [62]. Three functional Sp-1 binding sites and the TATA element are 
required for HIV promoter function [63]. However, while the two NF-KB binding 
sites are needed for maximal gene expression, they are not essential for virus 
replication [80]. 
Immune cell activation affects the replication of many lentiviruses 
[14,18,30,44,59,75,90-92,105,110]. Activated NF-KB has been reported to induce HIV 
gene expression in cells treated with phorbol esters or certain cytokines 
[18,30,44,75,91,92]. Using these methods, certain signal transduction pathways 
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are stimulated, such as those mediated by protein kinase C phosphorylation, 
which results in the activation of NF-KB [106]. Once activated, NF-KB can 
translocate to the cell nucleus and induce gene expression. In addition, the 
stimulation of signal transduction pathways involving cAMP have also been 
reported to augment HIV replication [19]. 
Activation of immune cells can also result in the inhibition of lentivirus 
replication. Treatment with a phorbol ester [79], bacterial lipopolysaccharide 
(LPS) [4,57], or interferon (IFN) [28,32,33,39,41,57,58,76,82,93,107] results in 
decreased replication of HIV. The overall effects of cellular activation on 
lentivirus replication depends, in part, on the cell type used for in vitro studies. 
For example, cellular activation with a phorbol ester [79] or LPS [57] inhibits HIV 
replication in primary human monocytes, but stimulates viral replication in 
chronically infected cell lines [18,94]. Treatment of primary human 
macrophages with IFN inhibits the early stages of HIV replication [33,58,76]; 
while activation of various cell lines by the same method inhibits late stages in 
the virus life cycle [33,93]. Therefore, HIV replication is regulated by activated 
cellular transcription factors which may vary depending on the specific signal 
transduction pathways stimulated within a particular host cell. 
Lentiviral gene expression can be divided into early and late stages 
[22,25,37]. During the early stage, low levels of transcription are induced by 
cellular transcription factors leading to the production of full-length viral 
transcripts. These transcripts are subsequently processed to remove non-coding 
intron sequences resulting in the formation of fully spliced transcripts. 
Therefore, regulatory proteins encoded by multiply spliced mRNAs are 
predominantly synthesized early after infection. Since early mRNA 
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transcription of HIV is thought to be mediated by cellular factors, the 
intracellular environment at the time of infection can determine the expression 
of viral regulatory proteins. The transition of gene expression from early to late 
is mediated by the viral regulatory protein. Rev, which stabilizes and transports 
full-length and singly-spliced transcripts to the cytoplasm of the cell [29]. This 
results in the predominance of incompletely spliced mRNAs encoding the viral 
structural proteins. Therefore, Rev is a negative regulator of its own synthesis, 
creating a balance between the synthesis of viral structural and regulatory 
proteins [25,37]. A critical level of Rev is required for the early to late transition 
of viral gene expression. Latently infected cells constitutively express low levels 
of Rev [95]. Thus, viral structural proteins are not produced resulting in a 
nonproductive infection. Therefore, it has been hypothesized that low levels of 
Rev are essential for the maintenance of a latent HIV infection in vivo [95]. 
The viral regulatory protein. Tat, transcriptionally activates HIV LTR gene 
expression creating a positive feedback loop which results in the production of 
high levels of viral mRNA and protein synthesis [21,22,25,37,64]. Tat 
transactivation requires the viral cis-acting sequence transactivation response 
element, or TAR [21,22,25,37,64]. The tat gene is encoded by two exons, although, 
only the first is required to produce a fully functional Tat protein. Tat is made up 
of two functional domains, and both are essential for transactivation. The first, a 
cysteine-rich domain, has been identified as the activation domain and is 
involved in conjugation of metal ions and Tat dimerization. The second is highly 
basic and functions in nuclear localization and binding of Tat to TAR. 
TAR is a stem-loop structure found in the 5' end of all viral mRNA species 
[21,22,25,37], Tat binds to a 3 nucleotide bulge near the terminal end of the stem. 
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and a 68 kDa cellular factor binds to the 6 nucleotide loop [70]. It appears that the 
68 kDa cellular factor mediates Tat-TAR interaction, since heterologous RNA-
protein binding sites substituted for TAR result in significant transactivation by 
chimeric proteins created from the fusion of Tat to the corresponding squence-
specific RNA-binding protein [109]. Tat-TAR interaction results in increased 
transcription initiation, as well as decreased premature transcription 
termination [3,60]. 
Post-transcriptional processing is a mechanism used by lentiviruses to 
generate many species of viral mRNA from the full-length genomic transcript 
[25,37]. Translation of specific HIV gene products occurs from differentially 
spliced mRNAs created from at least four splice donor sites and six splice acceptor 
sites [38,96]. The regulatory proteins. Tat, Rev, and Nef are encoded by a multiply 
spliced transcript approximately 2 kb in size. Structural viral proteins, Gag and 
Pol, are produced from unspliced transcripts, while singly spliced mRNAs encode 
Env and Vif. Cellular regulation of splicing events has not been clearly defined, 
but is thought to involve protein-RNA and protein-protein interactions between 
both specialized and general splicing factors and specific pre-mRNAs 
[61,69,81,108]. Splicing factor 2 and alternative splicing factor are two cellular 
factors which bind nonspecifically to RNA and promote the annealing of 
complementary RNA, therefore, they are required for the assembly and 
stabilization of spliceosomes [51,69]. Cell-specific differences in the 
concentrations or activities of these general splicing factors may be resposible 
for the regulation of alternative splicing [61,69,81,108]. 
The viral regulatory protein. Rev, is also involved in the regulation of 
alternative splicing events. Rev has been shown to increase the stability of 
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unspliced HIV mRNA [29], specifically inhibit the splicing of pre-mRNAs [51], 
and affect the transport of unspliced and single-spliced mRNAs from the nucleus 
to the cytoplasm [29]. Rev inhibits the assembly of functional splicing complexes 
by blocking the entry of U4, US, and U6 small nuclear RNAs into the spliceosome 
[51,52]. 
The specificity of Rev transactivation is determined by its requirement for 
interaction with the Rev response element (RRE), a 234-nucleotide RNA target 
sequence [21,22,25,37]. This sequence is specifically encoded in the env gene of 
unspliced and singly spliced HIV transcripts. Only a 66-nucleotide stem-loop 
portion of the RRE is essential for high-affinity binding of Rev and significant 
biological function, however, the entire RRE is needed for full biological activity 
in vivo [68]. 
Rev is produced from two coding exons and subsequently localizes to the 
cell nucleus [29]. Two domains which are required for its function have been 
described [66]. One, an arginine-rich domain, is involved in the specific binding 
of Rev to the RRE, as well as nuclear localization of Rev. Specifically, nuclear 
localization has been attributed to a central core region of this domain. A 
recessive negative phenotype is observed in Rev proteins which are mutated in 
this domain. The second domain mediates transport of specific mRNAs from the 
nucleus to the cytoplasm. Mutations in this domain result in a trans-dominant 
negative phenotype [66]. This phenotype is likely due to the binding of a mutant 
Rev to the RRE which is incapable of interaction with cell factors involved in 
nuclear transport. Theoretically, the trans-dominant negative Rev mutants may 
be of enormous therapeutic benefit. 
The regulation of lentiviral replication is complex, occurring at both the 
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transcriptional and post-transcriptional levels. Elucidation of the mechanisms 
important in lentiviral replication will likely increase our ability to understand 
the mechanisms which determine the establishment of persistent lentiviral 
infections and development of clinical disease. 
Equine infectious anemia virus 
In 1904, Vallee and Carre demonstrated that the causative agent of equine 
infectious anemia was a virus [9]. Prior to that time, the disease was believed to 
be the result of a nutritional deficiency. By the late 1970's, EIAV was classified as 
a nononcogenic retrovirus [43,112]. Currently this virus is a member of the 
lentivirus subfamily of retroviruses. Members of the genus Equus are the only 
known hosts for EIAV [40,111]. Transmission of the virus occurs via mechanical 
vectors, such as biting insects or hypodermic syringes, as well as vertically, 
however, not all foals of infected mares exhibit disease [46,49]. The incubation 
period has been shown to vary from five to 30 days in animals infected with EIAV 
field strains [SO]. Due to the relative ease of transmission, and reports that 
disease may be transmitted from inapparent carriers of EIAV [49], strict 
government regulations exist which require that horses are tested and found to 
be serologically negative for anti-EIAV antibody prior to interstate transport. In 
most states, animals testing positive must be quarantined or euthanized. 
Therefore, EIAV imposes an enormous emotional and economic impact on the 
equine industry. 
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Clinical disease and lesions 
Three outcomes of clinical disease, acute, chronic, and aclinical, have been 
described in EIAV-infected animals [40,42,45,54,72,83,111]. Acute disease is 
characterized by signs of fever, depression, anorexia, anemia, mucosal 
hemorrhages, and occassionally ventral edema. These animals may recover after 
several days or be febrile for one to three weeks until death occurs. Similar 
signs occur with the chronic form of disease, however, they are less severe, and 
occur in a cyclical manner. Chronically-infected animals may remain clinically 
quiescent for a variable period of time ranging from weeks to years between 
episodes of apparent clinical disease. Death may occur during any of the 
episodes, or the animal may recover permanently from signs of clinical disease. 
Animals with aclinical disease exhibit no apparent signs of disease, but remain 
infected carriers for life. 
In addition to the clinical signs mentioned above, a decline in erythrocyte, 
hemoglobin and hematocrit values occurs during febrile periods. The 
production, half-life, and iron-utilization rate of erythrocytes are decreased in 
infected animals. Serum iron is reduced while the iron-binding capacity of the 
plasma is enhanced. The number of hemosiderin-containing monocytes in the 
peripheral blood is increased. Persistent lymphocytosis often occurs in 
survivors, but usually follows a period of lymphopenia. Hypergammaglobulin­
emia, mainly comprised of IgG, occurs throughout the disease, however, peaks 
are usually observed during each clinical episode. 
Gross lesions which may be observed in an EIAV-infected animal include 
splenomegaly, lymphadenopathy, accentuated hepatic lobular architecture. 
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anemia, ventral edema, as well as serosal and mucosal hemorrhages [42,54,111], 
Acutely infected animals exhibit lymphoid necrosis and a lack of mature 
cells in the germinal centers and splenic follicles. Mild focal degenerative 
changes may be observed in the liver and kidney. Proliferation of lymphoid and 
reticuloendothelial elements occur in horses surviving several weeks of 
infection. Mitotic fîgures are typically observed in enlarged lymphoid follicles, 
while the lymph nodes contain a uniform population of lymphoid cells with 
increased numbers of plasma cells in the medullary cords. Mitotic figures are 
also present in the germinal centers of the spleen which is hypercellular with 
increased lymphoid and plasma cells in the red pulp. In the liver, Kupffer cells 
are activated and proliferating, and mitotically active lymphocytes and 
histiocytes accumulate in the periportal and intrasinusoidal areas. Large 
numbers of hemosiderin-containing cells are also found in the liver, circulation, 
and other tissues. Nearly any organ or tissue may exhibit perivascular lymphoid 
accumulations. Glomerulitis which is characterized by increased infiltration of 
neutrophils and thickening of glomerular tufts is also observed. The severity of 
lesions in an EIAV-infected animal is often determined by levels of virus 
replication in an infected animal, as well as the frequency of episodes of clinical 
disease. 
Many aspects of clinical disease with EIAV are the result of host immune 
responses to viral antigens [40,72]. Both the destruction of mature erythrocytes 
and the suppression of erythropoiesis result in anemia. Although the 
mechanism of erythropoietic suppression is unknown, erythrocyte destruction 
in an EIAV-infected animal is associated with the presence of complement 
components on the surface of these cells. Arabian foals with combined 
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immunodeficiency (CID), an autosomal recessive trait which results in a lack of T 
and B lymphocyte function, were used to show that a specific immune response, 
probably antibody, is required for C3 coating of erythrocytes in an EIAV-infected 
horse [103]. Therefore, an EIAV hemagglutinin is thought to mediate 
complement activation and subsequent erythrocyte lysis, as well as stimulate 
phagocytosis of erythrocytes by macrophages and neutrophils [102,103], In 
addition, during viremic episodes, virus-antibody complexes can be found in the 
plasma, and often glomerulitis results from deposition of these complexes. 
Deposits of anti-EIAV equine IgG and C3 occur in mesangial areas and along the 
basement membranes. 
Previously, clinical diagnosis was based upon physical and hematological 
examination, as well as the ability to confer clinical disease to suseptible horses 
inoculated with suspect blood or serum [42]. Today, the horse inoculation test has 
been replaced with serological analysis using immunodiffusion, which detects 
the presence of serum antibodies to p26, the major internal structural protein of 
EIAV [23]. It appears that viral persistence results in the continual stimulation of 
antibodies to p26 because they can be detected in nearly all persistently infected 
horses [73]. However, this immunodiffusion test is a relatively insensitive 
method for the detection of serum antibody levels, and EIAV-infected animals 
may mistakenly test negative using this method. More recently, a competitive 
ELISA test was developed which also detects the presence of serum antibodies to 
p26 [104]. For animals testing positive, treatment consists only of supportive 
measures as there is no known method which can successfully eliminate EIAV 
from the body. In addition, attempts have been made to develop a vaccine which 
can prevent disease, however, none have been successful [42]. 
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Persistence 
The role of the host defense mechanisms in the control of EIAV infection 
has not been clearly established. Using CID and normal foals, it has been shown 
that a specific immune response is required to terminate episodes of viremia in 
EIAV-infected animals [89]. It could not be determined whether the immune 
response involved cell-mediated and/or humoral immunity since these foals are 
deficient in both T- and B-lymphocyte populations. However, others have 
suggested that the cell-mediated immunity is involved in maintenance of an 
aclinical carrier state in EIAV-infected horses, since viremia and clinical disease 
are produced in carrier horses a few days after they are treated with either 
immunosuppressive drug, cyclophosphamide or dexamethasone [74]. 
Although a long-lasting EIAV-specific antibody response occurs, most 
infectious virus circulates as immune complexes in the serum, therefore the 
humoral immune response does not successfully eliminate infectious virus [71]. 
In fact, it is thought that one class or subclass of immunoglobulin may protect 
the virion from neutralization by another antibody which competes for the same 
group-specific antigenic site on the virus [72]. Thus, a mechanism for viral 
persistence has been proposed in which virus-antibody complexes provide a 
continuous source of infection for macrophages [40,72]. Phagocytosis of these 
complexes results in infection rather than inactivation of the virus. 
An alternate mechanism of viral persistence that has been proposed 
involves the cell to cell transfer of virus [40]. In this case, an intracellular 
infection is established prior to the appearance of antibody or cell-mediated 
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defense mechanisms. During cellular division, virus is passed into newly formed 
cells while remaining protected from the host immune responses. 
A third mechanism which may lead to viral persistence is antigenic 
variation to escape the host immune response [40,83,86]. This mechanism 
requires that mutations in the EIAV genome which result in antigenic 
modulation occur more rapidly than the development of specific host defense 
mechanisms which are capable of recognizing the new antigenic determinants. 
This model provides an explanation for the cyclical nature of clinical disease 
observed in EIAV-infected animals. Unique antigenic variants of the surface 
glycoprotein, gp90, have been detected during periodical relapses of clinical 
disease [56,87,100]. In addition, antigenic variants isolated from successive 
periods of clinical disease can be neutralized by specific monoclonal antibodies 
present after variant isolation [56]. The eventual cessation of clinical illness may 
be attributed to the recognition of antigenic epitopes common to all strains of 
EIAV by the host immune system [15]. The role of the neutralizing antibody in 
the selection of antigenic variants has not been clearly defined, however, it is 
not likely to be solely responsible for the selective pressure leading to antigenic 
variation in persistently infected animals. Structural differences which result 
in antigenic variation appear to be randomly distributed throughout the genome 
indicating that they are generated independent of host immune pressure [7,8]. If 
this is the case, the production of variant-specific neutralizing antibodies may 
simply be the result of the host immune system recognizing the predominant 
variant selected for by non-immunological factors [8]. 
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Replication 
In vivo replication of EIAV occurs in cells of the monocyte/macrophage 
lineage [53]. The cell receptor which mediates viral infectivity has not been 
identified. For in vitro study, primary horse macrophage cultures readily 
support the replication of wild-type isolates of EIAV, but cytopathic effects are 
often induced in these cultures which can be difficult to distinguish from normal 
cellular degeneration [S3]. As a result, isolates of EIAV are often adapted for 
growth in other cell-types, such as equine dermal cells or kidney cells which can 
be maintained in culture for extended periods of time. Changes in host cell 
tropism associated with culture-adapted strains of EIAV often result in decreased 
viral virulence [6]. Viral determinants of host cell tropism have not been 
identified. Although significant differences in the nucleotide sequence of the 
surface region of the envelope gene, gp90, have been observed among wild-type 
and culture-adapted strains, these differences were not responsible for 
determining cell tropism in vitro [88]. More recently, hypervariable regions 
were identified in the gp90 region of the env gene, as well as the LTR of isolates 
differing in cell tropism [1,5]. Hypervariability in this region resulted in the 
presence of different types of enhancer sequences in the LTR among these 
various isolates. Therefore, variation in elements which regulate EIAV 
replication may be important in determining host cell tropism. Further work is 
needed to clearly deflne the mechanisms responsible for determining host cell 
tropism. 
The virion structure of EIAV ranges from 90 to 200 nm in diameter, and 
consists of a smooth glycoprotein envelope surrounding a pleomorphic. 
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electron-dense core which is 40 to 80 nm in diameter [35]. EIAV replication is 
similar to that of other lentiviruses described above. 
The genome of EIAV is approximately 9 kb in length and encodes the Gag, 
Pol, Env, Tat, and Rev proteins, in addition to S2, an open reading frame whose 
function is undefined (Figure 2) [97]. Like HIV, EIAV gene expression is complex, 
and involves transcriptional regulation by both host and viral factors, as well as 
post-transcriptional processing to generate many species of transcripts from 
genomic RNA. A general model of transcriptional products is shown in Figure 2, 
however, transcription patterns have been shown to vary depending on cell-
type and virulence of the strain [84,85,97]. Viral proteins, Gag and Pol, are 
produced from the full length genomic 8.2 kb transcript. The 4.0 kb mRNA 
encodes the Env protein, and the regulatory proteins are produced from the 2.0 
and 1.8 kb mRNAs. The predominant transcripts detected in a persistently 
infected canine thymus cell line are 8.2, 5.0, 4.0, 2.0 and 1.8 Kb in length [84,85]. 
Currently the significance of the unique 5.0 kb transcript detected in these cells 
is not known. In addition, only three transcripts, 8.2 kb, approximately 4.0 kb 
and 1.5 kb in length, are detected in EIAV-infected feline cells [27] and fetal 
donkey dermal cells [97]. Culture-adapted strains have been utilized to determine 
all transcription patterns which have been described to date, therefore, the 
relationship between variability in transcription and EIAV pathogenesis and 
persistence is not known. 
As mentioned above, cellular factors are important in the regulation of 
lentiviral gene expression, and in the shift from a non-productive, or latent, 
infection to a productive one. The regulation of EIAV replication is not well 
characterized. Both a negative regulatory element and enhancer sequences are 
Figure 2. Schematic representation of tlie EIAV provirus and predominant EIAV 
mRNA transcripts (Revised and reprinted from Alexandersen and 
Carpenter, 1991 with permission). Numbering of nucleotides is 
based on the available Genbank sequence of EIAV Wyoming [48]. 
The total proviral genome, including both LTRs, is 8229 nucleotides. 
The locations of the two complete LTRs (nucleotides 1-321 and 7909-
8229),  the open reading frames gag (nucleotide 387-1922),  pol 
(nucleotide 1682-5119), env (nucleotide 5303-7888), SI (nucleotide 
5123-5272), S2 (nucleotide 5283-5480), and S3 (nucleotide 7234-7638) 
are indicated. S3 is in reading frame 1; pol, S2, and env are in 
reading frame 2; and gag and S2 are in reading frame 3. The 
putative cleavage site at nucleotide 6643 in the env gene is indicated 
as a vertical arrow. The hypervariable region in the gp90 surface 
glycoprotein spanning nucleotide 6176 to 6343 [1,87] is shown as a 
hatched horizontal bar. The unspliced mRNA encoding gaglpol, the 
single-spliced mRNA encoding env, the double-spliced tat (SI) 
mRNA [27], and the triple-spliced rev (S3) mRNA [113] are shown at 
the bottom. 
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present in the EIAV LTR [26]. More recently, ets/PEA3 consensus sequences 
which are capable of binding a cellular protein identifîed as PU.l were identified 
in the EIAV LTR [13,14]. PU.l mediates increased EIAV promoter activity in 
monocyte and B-lymphocyte continuous cell lines treated with a phorbol ester 
[14]. An AP I site has also been identified in the EIAV LTR which may be 
involved in mediating promoter activity [14]. Highly variable regions have been 
identified in the EIAV LTR which result in the presence of different enhancer 
sequences among various isolates [S]. Further work is needed to clearly define 
the cellular factors involved in the regulation of EIAV gene expression. 
The EIAV regulatory protein. Tat, trans-activates LTR-mediated gene 
expression. Even though it is less complex in structure compared to that of other 
lentiviruses, EIAV Tat mediates complex regulatory functions [27]. Two exons are 
required to encode a functional Tat. Functional domains of EIAV Tat are similar to 
those described above for HIV Tat, except the cysteine-rich domain is not present. 
This domain is described as the activation domain which mediates Tat 
dimerization and metal ion binding in the HIV Tat [11,36,98]. A core region is 
thought to serve as the activation domain for the EIAV Tat, while a basic region 
functions in Tat-TAR binding. Therefore, the EIAV Tat is capable of fully 
transactivating EIAV LTR without the cysteine-rich region [11]. 
The TAR element is located in 5' end of all EIAV transcripts. Its predicted 
hairpin like structure is considerably smaller in size than that of HIV, and lacks 
the characteristic bulge which is present in the HIV TAR [12]. However, non-
Watson-Crick, U-G, base pairing occurs in the EIAV TAR, and it has been 
suggested that this region represents the functional counterpart of the HIV TAR 
bulge [12] which mediates Tat binding. In addition, like the HIV TAR, the 
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secondary structure of EIAV TAR has been shown to be essential for Tat 
transactivation. The involvement of cellular factors in EIAV Tat transactivation 
has not been investigated. 
Another transactivating EIAV regulatory protein, Rev, is important in the 
transition from early to late gene expression. As previously mentioned, Rev 
mediates the stabilization and cytoplasmic transport of unspliced and singly 
spliced transcripts [29]. EIAV Rev is produced from two coding exons, however, 
only the 3' exon is essential to produce a functional protein [31]. Although the 
EIAV Rev functions in a manner similar to that of other lentiviruses, it possesses 
a much smaller arginine-rich domain [113] and its activation domain shares very 
little amino acid homology with that of other lentiviruses [31,67]. Variant Rev 
genotypes have been identified from an in vivo isolate of EIAV, and it has been 
hypothesized that these genotypes confer recessive negative Rev phenotypes [1]. 
Since structural proteins would not be expressed by viruses exhibiting this 
phenotype, superinfection and rescue of the defective phenotype could 
theoretically occur by a competent virus [1]. This may provide a possible 
mechanism which results in the shift from a latent to a productive infection. 
Additional regulation of EIAV gene expression may occur at the 
translational level. EIAV Tat is produced from two coding exons [27,85]. 
Translation of Tat is initiated within the first exon at a non-AUG initiation codon 
located on the 5' side of the first major splice donor site (Figure 2). As a result of 
its location, the Tat initiation codon is present in all classes of EIAV transcripts. 
Consequently, since multi- and bicistronic messages are utilized for the 
expression of various EIAV proteins, it has been hypothesized that leaky 
ribosome scanning of the non-AUG Tat initiator codon must occur for the 
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expression of EIAV structural and regulatory proteins, other than Tat [10]. 
Genetic mutation of the Tat initiator codon to AUG results in increased Tat 
production from bicistronic mRNAs with a simultaneous reduction in the 
translation of the downstream cistron which encodes Rev [10]. Therefore, leaky 
ribosome scanning is a mechanism which may indirectly regulate gene 
expression by controlling the rate of translation of viral regulatory proteins. 
The severity of clinical disease and lesions seems to be correlated with the 
levels of EIAV replication in vivo. Therefore, understanding the mechanisms 
which regulate viral replication will contribute to our understanding of EIAV 
pathogenesis. Both viral and host factors appear to be involved in determining 
the outcome of clinical disease in EIAV-infected horses. We hypothesize that 
there is biological variation in cellular factors which control EIAV replication 
early after infection. The overall objective of this research is to characterize the 
effect of host cell variability on EIAV replication in vitro. 
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BACTERIAL ENDOTOXIN DECREASES REPLICATION OF EQUINE 
INFECTIOUS ANEMIA VIRUS IN PRIMARY HORSE MACROPHAGE CULTURES 
A paper submitted to the Archives of Virology 
Teresa A. Smith, Peggy Miller Graber, and Susan Carpenter 
S u m m a r y  
Equine infectious anemia virus (EIAV) is a member of the lentivirus 
subfamily of retroviruses. Lentiviruses replicate in cells of the immune system, 
and activation of immune cells has been shown to modulate virus replication. 
The current studies were undertaken to determine the effects of macrophage 
activation on EIAV replication in vitro. Primary horse macrophage cultures 
(HMC) were established from 20 different horses, infected with an avirulent 
strain of EIAV, and stimulated with 5 ^g/ml of bacterial endotoxin. Supematants 
collected from HMC were assayed for the presence of tumor necrosis factor-a 
(TNF-a), and titers of infectious virus. Results indicated that EIAV replication in 
vitro varied significantly (p ^ 0.0001) from horse to horse, regardless of the 
treatment of HMC. Also, EIAV replication was significantly (p < 0.0001) decreased 
in HMC stimulated with bacterial endotoxin as compared to untreated HMC. No 
significant correlation was found between virus replication and production of 
TNF-a following treatment of virus-infected cells with bacterial endotoxin. 
However, inhibition of EIAV replication was more dramatic when basal levels of 
TNF-a were detected at the time of infection. These results suggest that cellular 
factors present in activated macrophages may inhibit EIAV replication at an 
early stage in virus replication. 
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I n t r o d u c t i o n  
Equine infectious anemia virus (EIAV) is a member of the lentivirus 
subfamily of retroviruses. Like other lentiviruses, EIAV has a complex genome 
organization, and replicates in cells of the monocyte/macrophage lineage 
[10,18,23,37,38,40,49]. EIAV produces a variable disease course in infected horses, 
described as acute, chronic, or aclinical. The acute form of the disease is 
characterized by viremia, hemorrhage, pyrexia, and a rapid onset of death. In 
the chronic form of disease, horses show clinical signs similar to the acute form, 
but they are less severe, occur in a cyclic manner, and include anemia. Animals 
with aclinical disease exhibit no apparent signs of disease [20,23,40]. Both viral 
and host factors are thought to be important in determining the clinical outcome 
of EIAV infection. Viral factors include the virulence of different isolates, 
antigenic variation to escape host immune surveillance, sequence heterogeneity 
in viral regulatory elements, as well as co-existence of varying genotypes 
[1,2,24,27,28,42,50]. Host factors are less well defmed, but likely include the 
immune competence and major histocompatibility complex haplotype of the 
horse [42]. In addition, qualitative differences in cellular co-factors that are 
involved in viral gene regulation may be contributing host factors. For example, 
variation in human immunodeficiency virus (HIV) replication has been shown 
to occur in macrophages isolated from different sites throughout the body, as 
well as among individual donors [41]. This suggests that cellular differences, 
whether within an individual or among individuals, can have a significant 
impact on viral replication. These differences may account for variability in the 
clinical manifestations of disease. 
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Lentivirus gene expression and replication often depends on activation of 
host cells harboring pro viral DNA [35,47]. Monocytes/macrophages can be 
activated using a variety of methods including immune stimulation, or treatment 
of cells with bacterial endotoxin or phorbol esters. These events stimulate 
various signal transduction reactions which activate certain protein kinases 
responsible for phosphorylation, and consequently, activation of cellular 
transcription co-factors. Cellular co-factors regulate transcription of integrated 
proviral DNA as well as cellular genes [33]. For example, it has been shown that 
treatment of HIV-infected monocytes with phorbol esters increases virus 
replication. An activated host nuclear regulatory factor, NF-KB, binds to the long 
terminal repeat (LTR) of HIV resulting in increased viral transcription [34]. 
Additional cellular transcription factors have been shown to affect the 
regulation of other lentiviral genes via interaction with the viral LTR. Cellular 
proto-oncogene proteins JUN and FOS appear to be directly involved in 
regulation of visna virus gene expression in phorbol ester treated U937 cells, a 
monocytic cell line, through an AP I recognition site [21,51]. A potential AP I 
site present in the LTR of feline immunodeficiency virus (FIV) is thought to be 
involved in protein kinase C-mediated activation responses, whereas a putative 
ATF site has been identified which may be important in protein kinase A-
mediated responses [55]. 
Recently, it has been shown that the EIAV LTR can be transcriptionally 
activated by treating transfected HeLa cells with a phorbol ester, and that 
activation is mediated through an ets/PEA3 motif present in the LTR [8]. 
Therefore, EIAV is similar to other lentivinises in that it can be transcriptionally 
regulated by cellular activation events. However, the factors which regulate 
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EIAV replication in primary macrophage cultures have not been defined. One of 
our overall goals is to identify host and viral factors which regulate EIAV 
replication. In the present study, we examined the effect of macrophage 
variability and activation on EIAV replication in HMC in vitro. 
Materials and Methods 
Horses 
Twenty horses from the Iowa State University Animal Science Department 
were used to examine the effect of the donor horse and macrophage activation on 
permissiveness for viral replication in vitro. Sixteen out of the 20 horses were 
Quarterhorses and the other four were Arabian. The horses ranged in age from 
two to 23 years, four were mares, and 16 were geldings. Sera from each animal 
were screened for antibody titers to equine herpesvirus (EHV) -1, -2, -3 and -4 
(University of Kentucky Livestock Disease Diagnostic Center, Lexington, KY) 
(Table 1), and EIAV (Iowa State University Diagnostic Laboratory, Ames, lA). All 
horses were negative for EHV-3, and EIAV. 
Additional donor horses were housed at the Iowa State University 
Veterinary Teaching Hospital. 
Cells 
Whole blood was obtained by jugular venipuncture and mononuclear 
leukocytes were banded by centrifugation at 750 x g on a discontinuous 
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histopaque gradient [3]. Cells were resuspended in Dulbecco's MEM (DMEM) 
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containing 20% horse serum and 10% newborn calf serum (NCS), seeded at 2 x 10 
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cells/cm in 24 well tissue culture plates, and allowed to adhere overnight at 
37°C. The following day, nonadherent cells were removed from the cultures by 
washing twice with Hank's buffered saline solution (HBSS) containing 2% fetal 
calf serum (PCS). Cells were maintained in DMEM containing 20% horse serum 
and 10% NCS. 
Equine dermal (ED) cells (ATCC #CCL57) were grown in DMEM 
supplemented with 20% PCS. 
Virus inoculation and HMC activation 
For virus inoculation, HMC were treated at 48 hours with 8 ng/ml 
polybrene and infected with 1-10 x 10^ focus forming units of an avirulent strain 
of EIAV (MA-1). The next day, cells were washed with HBSS containing 2% PCS to 
remove cell-free virus. Supernatant samples were collected every other day for 
six days post-infection, and tested for the presence of virus as described below. 
EIAV infected or uninfected HMC's from each animal were treated with either 
fresh medium, medium containing S pg/ml Escherichia coli K235 endotoxin 
(Sigma Chemical Company, St. Louis, MO), or 10% conditioned medium. 
Supernatant samples were collected from all wells immediately prior to, and four 
hours following HMC activation and tested for the presence of TNP-a as described 
below. Por preparation of conditioned medium, HMC were established from a 
donor pony and stimulated with S |Xg/ml of E. coli K23S endotoxin. Eight hours 
post-stimulation, supernatants were collected, clarified by centrifugation. 
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aliquoted, and frozen at -70°C. Conditioned medium was found to contain 12,000 
Units/ml of TNF-a. 
Assays for virus replication 
Culture supernatant samples were clarified by centrifugation at 2000 x g 
for S minutes, and virus replication was measured using a reverse transcriptase 
(RT) assay as previously described [3]. Briefly, 10 ^1 of HMC supernatant was 
incubated with 30 p.! of RT assay solution for two hours at 37°C, and 8 ^1 of the 
mixture was spotted onto DE81 ion exchange paper (Whatman Inc., Clifton, N.J.). 
The paper was washed three times with 0.35 M Na2HP04, and once with 95% 
ethanol. Positive RT activity was observed by exposing the DE81 paper to film at 
•70°C. Positive controls used for each RT assay included the MA-1 inoculum and 
supernatant samples from EIAV-infected ED cell cultures. Negative controls 
included supernatant samples from non-infected HMC and non-infected ED cell 
cultures. 
Infectious virus was quantitated using a focal immunoassay (FIA) which 
employed a chromogenic method of detection rather than the fluorogenic 
method previously described [5]. HMC supernatant samples were serially diluted 
ten-fold in DMEM containing polybrene (8 |xg/ml) and added to cultures of ED 
cells. Five days post-inoculation, ED cells were washed once with TNE buffer (10 
mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.5), fixed with 100% methanol for ten 
minutes, and washed again with TNE. The primary antibody, an EIAV 
convalescent horse serum (1:800), was added to the cells, and allowed to bind for 
at least one hour at room temperature. Unbound serum was removed by washing 
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with TNE and the cells were incubated for 30 minutes at room temperature with 
the secondary antibody, horseradish peroxidase-conjugated goat anti-horse IgG 
polyclonal antibody (1:800) (Organon Teknika Corporation, Durham, NC). 
Unbound secondary antibody was removed as before, and AEC substrate, 
consisting of 0.2 mg/ml of 3-amino-9-ethylcarbazole and 0.01% hydrogen 
peroxide in 0.05 M sodium acetate solution (pH 5.0), was added. The substrate was 
allowed to react for ten minutes in the dark at room temperature, the cells were 
washed with tap water, and allowed to dry at room temperature. Foci of infected 
cells were counted using a dissecting microscope. 
TNF-a Bioassay 
L929 cells (ATCC #CCL1 NCTC Clone 929) were seeded at 4 x 10^ cells per well 
in 96 well tissue culture plates in Eagle's Minimum Essential Medium (MEM) 
containing 10% horse serum and incubated for 24 hours at 37°C. HMC super­
natant samples were diluted 1:5 and 1:50 in MEM containing 3 pg/ml actinomycin 
D, and 100 ^1 of each dilution was added to duplicate wells of L929 cells. Cells were 
incubated overnight at 37°C, fixed with 50 pi 10% phosphate buffered formalin, 
washed twice with 0.85% sodium chloride, and stained with a gravity filtered 
solution of 0.2% crystal violet and 0.74% formaldehyde in distilled water. After 
washing the cells with tap water, plates were dried overnight at room temper­
ature. The next day, 100 p,l of a 1:1 solution of phosphate buffered saline:95% 
ethanol was added to each well of the plate, and the absorbance of the solution 
was read at 550 nm. As a positive control, ten-fold serial dilutions of recombinant 
murine TNF-a (rTNF-a) (Genzyme, Cambridge, MA) were added to duplicate wells 
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of each test plate containing L929 cells. As negative controls, medium alone, and 
one unit murine rTNF-a in the presence of anti-murine TNF-a antibody 
(Genzyme, Cambridge, MA) were added to duplicate wells of each test plate. 
Statistical Analysis 
Comparison of virus replication among horses and treatments was done 
using the analysis of variance to determine the statistical significance of 
differences between the means of the samples. To examine the relationship 
between TNF-a production and virus replication, a linear model was used to 
determine if a correlation existed between the means of the samples. 
R e s u l t s  
TNF-a production in primary HMC 
To examine the effects of macrophage activation on EIAV replication, it 
was necessary to establish an independent measurement of macrophage 
activation. We chose to use cytokine production (TNF-a) as a measurement of 
macrophage activation following treatment of cells with bacterial endotoxin or 
10% conditioned medium. A TNF-a-sensitive murine cell line is widely used in 
the L929 bioassay to quantitate the amount of TNF-a present in biological samples 
[6]. Therefore, initial experiments were done to establish that the assay was 
sensitive and specific for detection of equine TNF-a. A standard curve derived 
from serial dilutions of known concentrations of recombinant murine TNF-a was 
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used to quantitate equine TNF-a with the L929 bioassay. Also, anti-human and 
anti-murine TNF-a antibodies were capable of blocking the cytotoxic effects of 
equine TNF-a on L929 cells (data not shown). Kinetic studies indicated that basal 
TNF-a production in HMC increased with prolonged culture, although levels of 
TNF-a produced overall were low (data not shown). In addition, HMC could be 
activated by treatment with S ^g/ml bacterial endotoxin, as measured by 
increased TNF-a production, when treated at 24 hours or 72 hours following 
culture (Figures lA and C). Cells treated with bacterial endotoxin at 48 hours 
after establishing culture were not as consistently stimulated (Figure IB). In 
order to examine the effect of macrophage activation on virus-infected cells, 
subsequent experiments were done stimulating cells at 72 hours post-culture, 
equivalent to 24 hours post-infection. 
EIAV replication varied among horses 
The MA-1 isolate of EIAV was derived from a horse experimentally 
inoculated with a field isolate of EIAV and selected for in vitro replication on 
equine dermal cells [3,4]. Previously, it was reported that MA-1 did not replicate 
to detectable levels in primary HMC [3], and studies were initiated to define the 
basis for regulation of MA-1 replication in primary HMC. Preliminary 
experiments compared MA-1 replication in HMC derived from two different 
horses, and the effect of the source of cell culture sera. Results indicated that 
levels of MA-1 replication varied with respect to both cell and serum sources 
(data not shown). Together, these results suggested that virus replication may be 
regulated, in part, by host cell-specific factors which vary under certain culture 
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conditions. Further experiments established enhanced virus replication in 
culture media supplemented with 20% horse serum and 10% newborn calf serum 
(data not shown). Using these culture conditions, we examined the influence of 
the donor horse and macrophage activation on MA-1 replication in HMC in vitro. 
Blood was collected from each of twenty horses on three separate 
occassions and cells were infected with MA-1. Virus replication was quantitated 
by RT activity, and results from two of the 20 horses are shown in Figure 2. 
Differences between the horses included the rate of virus replication, the level 
of virus replication, and the effect of macrophage activation on virus 
replication. Reverse transcriptase was first detectable at four days post-infection 
in HMC from horse #14, whereas RT activity was not detected until day 6 in HMC 
established from horse #13. Treatment with endotoxin or 10% conditioned 
medium appeared to reduce virus replication in HMC from horse #14, but the 
reduction was not as evident as was observed in HMC from horse #13. Due to the 
relatively low sensitivity of the RT assay, virus replication was also quantitated 
by using the FIA [5], which is approximately 100-fold more sensitive than the RT 
assay. Data obtained from all horses showed that MA-1 replication in untreated 
HMC varied significantly (p < 0.0001) among the 20 different horses (Figure 3). 
Overall, the horses could be separated into three groups based on high, medium, 
and low levels of MA-1 replication in untreated HMC. The majority of the animals 
4 5 5 (n=17) fell into the high level group, and produced 10 ' to 10 focus forming 
units/ml (ffu/ml) of culture supernatant. Two horses in the middle group 
3 5 4 produced 10 to 10 ffu/ml. The low group contained only one horse, #5, which 
3 produced 10 ffu/ml of sample. No correlation was observed between levels of 
EIAV replication in HMC established from different horses and the age, sex, or 
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breed of the horse. In addition, no relationship was found between serological 
antibody titers to EHV and levels of EIAV replication. This suggested that there 
are intrinsic differences among horses at the cellular level which are involved 
in regulation of virus replication. 
Macrophage activation decreased EIAV replication 
Replication of some lentiviruses has been shown to increase following 
activation of macrophages [33,35,45], and it was of interest to examine the effects 
of macrophage activation on EIAV replication. HMC established from the group 
of horses described above were infected with MA-1, and stimulated 24 hours later 
with either bacterial endotoxin or 10% conditioned medium. In nineteen out of 
twenty horses, MA-1 replication significantly (p < 0.0001) decreased following 
HMC activation. Results from the RT and FIA indicated virus replication 
decreased 10- to 100-fold when HMC were treated with bacterial endotoxin or 
conditioned medium (Figures 2 and 3). One horse, #5, showed essentially no 
change in permissiveness for MA-1 between treated and untreated HMC. Coin-
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cidentally, this horse produced only 10 ffu/ml MA-1 from untreated HMC, the 
lowest titer of all 20 horses. To determine whether the decline in EIAV replic­
ation in treated HMC was due to inability of macrophages to be activated, TNF-a 
production was measured in HMC supernatant samples from eight out of twenty 
horses (#1, 5, 7, 8, 9, 13, 15, and 19). These eight were chosen because they best 
represented the data obtained from HMC of all horses used for the experiments. 
All samples from HMC treated with endotoxin contained significantly higher 
amounts of TNF-a than samples from untreated wells (data not shown), indicating 
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that cultures were activated by this method. 
EIAV replication and TNF-a production 
Replication of other lentiviruses has been shown to be affected by TNF-a 
[15,25,33,45], so experiments were done to determine if there was a relationship 
between TNF-a production and virus replication in HMC established from the 
same animal. No significant correlation was observed between levels of TNF-a 
produced and levels of virus replication in activated HMC (Figure 4). Also, there 
was no significant difference between levels of TNF-a produced by MA-1 infected 
and non-infected cells, indicating that MA-1 replication had no significant effect 
on TNF-a production in activated HMC (data not shown). However, when we 
observed detectable levels of TNF-a at the time of infection, prior to activation of 
HMC, there was a greater than ten-fold decrease in MA-1 replication following 
endotoxin treatment (Figure 5). This suggested that basal levels of TNF-a present 
at the time of infection may influence permissiveness for EIAV replication in 
HMC. 
D i s c u s s i o n  
Horse macrophage cultures established from twenty different horses 
varied significantly (p < 0.0001) in permissiveness for EIAV replication in vitro. 
The differences were not correlated with age, breed, sex, or previous medical 
history. Individual environmental conditions present at the time of blood 
collection were minimized by sampling each horse three times over a four month 
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period. Together, these results suggest that there are intrinsic differences 
among horses at the cellular level which regulate virus replication. These 
cellular differences may play a crucial role in determining the permissiveness 
for EIAV among horses, and as a result, affect the outcome of clinical disease. 
Previously, others have found significant variation among donors of primary 
human macrophages [41,44] and human peripheral blood lymphocytes [14] in 
susceptibility to HIV infection. Differences in susceptibility among donor 
macrophage cultures was attributed to variability in levels of in vivo activation 
and/or differences among individuals in susceptibility to HIV infection. No 
correlation was observed between virus replication and levels of macrophage 
activation as measured by production of TNF-a following treatment. However, 
the decrease in EIAV replication in stimulated macrophages as compared to 
untreated macrophages suggests that regulation of viral replication is controlled, 
in part, by cellular activation signals. 
Activation of HMC using bacterial endotoxin resulted in significantly (p < 
0.0001) decreased replication of EIAV. Similarly, it has been reported that 
treatment of HIV-infected monocytes with bacterial lipopolysaccharide (LPS) 
decreased virus replication [29,30]. Further experiments are needed to determine 
whether bacterial endotoxin is directly inhibiting EIAV replication, or if it has 
indirect negative regulatory effect on virus replication. It is possible that host 
cell factors activated as a result of endotoxin treatment are capable of down-
regulating EIAV replication. Pathways important in regulation of EIAV 
transcription are not well characterized, however both negative regulatory 
elements and enhancer sequences have been identified in the EIAV LTR 
[7,8,12,13], Sequences in the U3 region of the LTR have been shown to act as 
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negative regulatory elements in phorbol ester stimulated Hela cells [8], and it was 
suggested that interaction of cellular proteins with this region may exert either 
a positive or negative regulatory effect, depending on the cell type or condition 
studied [8]. Thus, it is important to note that the present experiments examined 
EIAV replication in primary HMC, whereas previous studies of EIAV transcription 
have utilized non-equine cell lines. In addition, there is considerable variation 
among different isolates of EIAV in both the number and type of enhancer 
sequences present in the LTR, which may differentially regulate EIAV 
replication [2,8,12]. Both variation in EIAV LTR sequences as well as differences 
in host cell types likely contribute to the overall levels of viral replication in 
vitro. 
Treatment of HMC with 10% conditioned medium also decreased replication 
of EIAV. This was somewhat surprising as it has been reported that activation of 
cells using phorbol esters, cytokines or supernatants from LPS-stimulated 
monocytes or T-lymphocytes increases replication of many lentiviruses, such as 
HIV, simian immunodeficiency virus, FIV and visna virus [33,48,51,55]. Induction 
of HIV replication following activation with supernatants from LPS-stimulated 
monocytes was attributed to the presence of TNF-a, which induces the cellular 
transcription factor NF-KB and upregulates HIV transcription through specific 
sequences in the HIV LTR [32,48]. The conditioned medium used in the present 
study was found to contain relatively high levels of TNF-a. Therefore, the failure 
of conditioned media to increase EIAV replication may reflect differences in 
regulatory elements present in the EIAV LTR as compared to the HIV LTR. For 
example, the MA-1 LTR does not contain any NF-KB or SP-1 enhancer sequences 
[2], which are critical elements in transcriptional regulation of HIV 
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[11,32,34,35,45]. 
It is possible that activated macrophages may exert indirect antiviral 
effects on EIAV mediated by interferon (IFN). TNF-a [26], as well as bacterial 
endotoxin [54], are capable of inducing IFN production by macrophages. Also, 
IFN has been shown to have antiviral effects on retroviruses [9,43,56], including 
HIV [16,17,19,22,29-31,39,46,52,53]. IFN treatment of HIV-infected primary human 
macrophages is thought to affect early steps in the virus replication cycle, 
between adsorption and reverse transcription, resulting in reduced viral DNA 
synthesis [17,30,36]. Interestingly, inhibition of EIAV replication was most 
dramatic in activated HMC when basal levels of TNF-a were detected prior to 
infection, suggesting that inhibition occurs during early stages of EIAV 
replication. Alternately, activated macrophages may be less susceptible to EIAV 
infection due to changes which result in inhibition of viral binding and/or 
entry. It has been suggested that LPS treated T-lymphocytes have fewer CD4 
molecules on the surface, resulting in decreased HIV entry and subsequent 
replication in these cells [14]. Further studies examining the various stages of 
EIAV replication in vitro are needed to better understand the decline in EIAV 
replication which occurs in activated HMC. 
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Figure Legends 
Figure 1. Quantitation of equine TNF-a using the L929 bioassay as described in 
the text. TNF-a production in HMC activated with 5 )ig/ml of bacterial endotoxin 
after (A) 24, (B) 48, or (C) 72 hours in culture. Supernatant samples were 
collected 4 and 24 hours after endotoxin treatment from duplicate wells of HMC, 
and levels of TNF-a in each sample were measured. Each bar represents the 
mean data from duplicate wells of HMC established from donor horses on three 
separate occassions. The stimulation index was calculated as: 
(Units TNF-g from treated HMC) - (Units TNF-a from untreated HMC^ 
(Units of TNF-a from untreated HMC). 
Figure 2. Reverse transcriptase activity in EIAV-infected HMC. HMC established 
from two horses, #13 and #14, were infected with EIAV at 48 hours (Day 0). The 
following day, cells were washed with HBSS containing 2% FCS to remove cell 
free virus, and treated with the following: 5 ^g/ml of bacterial endotoxin (Endo); 
10% conditioned medium (10%); or media alone (NT). Culture supernatant 
samples collected prior to infection (Pre), and every other day for six days, were 
tested for reverse transcriptase activity as described in the text. 
Figure 3. EIAV replication in untreated (solid circle) and endotoxin treated (open 
circle) HMC established from twenty horses. HMC were infected with EIAV 48 
hours after culture, and treated with 5 p.g/ml of bacterial endotoxin 24 hours 
later. Supernatant samples were collected six days post-infection, and infectious 
virus was quantitated using FIA described in the text. Results represent the mean 
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of data from samples of duplicate cultures establ ished on three separate 
occassions. Error bars represent the standard error of the mean. 
Figure 4. Correlation between TNF-a production and EIAV replication following 
treatment of HMC with bacterial endotoxin. HMC established from eight horses 
were infected with EIAV 48 hours after culture, and treated with S )ig/ml of 
bacterial endotoxin 24 hours later. Levels of TNF-a present in HMC supernatant 
samples collected four hours following endotoxin treatment were determined 
using the L929 bioassay. Titers of EIAV in HMC supernatant samples collected 
from the same well at six days post-infection were determined using the FIA 
described in the text. Each point represents data from a single well. 
Figure 5. Basal levels of TNF-a and inhibition of EIAV replication in HMC 
activated with bacterial endotoxin. HMC established from eight horses (#1, S, 7, 8, 
9, 13, 15, and 19) were infected with EIAV at 48 hours and treated with 5 ^g/ml 
bacterial endotoxin at 72 hours. Supernatant samples collected prior to treatment 
with bacterial endotoxin were assayed for TNF-a (solid bars) using the L929 
bioassay. Titers of infectious virus were determined from supernatant samples 
collected six days post-infection using the FIA. Stippled bars represent the 
difference in virus titer between non-treated and endotoxin-treated HMC from 
the same horse. Each bar represents the mean of data obtained from duplicate 
cultures on three separate occassions. 
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Table 1. Antibody titers to equine herpesviruses^ 
Horse EHV-1 EHV-2 EHV-4 
1 128 Neg 128 
2 4 NA^ 8 
3 16 4 8 
4 32 16 8 
5 4 NA 16 
6 16 8 16 
7 32 8 16 
8 16 8 32 
9 8 Neg 4 
10 128 4 64 
11 8 16 8 
12 64 4 32 
13 64 Neg 16 
14 64 8 16 
15 8 16 <8 
16 NDC ND ND 
17 16 16 16 
18 4 NA <8 
19 64 8 32 
20 ND ND ND 
^ Sera samples were obtained from 18 out of the 20 horses and tested for 
the presence of antibody to equine herpesvirus. Results are expressed as 
the reciprocal of the highest dilution of serum which gave a positive result. 
^ Serum sample was toxic to cells used for the assay, and therefore, was 
not analyzed (NA). 
^ Not determined (ND). 
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ENDOTOXIN TREATMENT OF HMC RESULTS IN ALTERNATE SPLICING OF EQUINE 
INFECTIOUS ANEMIA VIRUS REGULATORY GENES AND DELAYS THE APPEARANCE OF 
TRANSCRIPTS ENCODING VIRAL STRUCTURAL PROTEINS 
A paper submitted to Virology 
Teresa A. Smith and Susan Carpenter 
A b s t r a c t  
Cellular activation has been shown to affect the replication of 
lentiviruses. Previously we observed that equine infectious anemia virus (EIAV) 
replication was inhibited in primary horse macrophage cultures (HMC) activated 
with bacterial endotoxin. The current experiments were designed to determine 
the mechanism of inhibition of EIAV replication in activated HMC. Primary HMC 
were treated with serially diluted bacterial endotoxin and infected with an 
avirulent strain of EIAV. Total cellular DNA and RNA were isolated from HMC at 
six hours, 18 hours, 43 hours and six days following infection, and the 
polymerase chain reaction (PCR) and the reverse transe ription-PCR were used to 
amplify EIAV proviral DNA and mRNA sequences, respectively. Results indicated 
that the reverse transcription of proviral DNA early after infection was not 
affected by endotoxin treatment of HMC. Also, there were no quantitative 
differences in multiply-spliced mRNAs until six days post-infection. However, 
variable splicing patterns dependent on both time and dose of endotoxin were 
observed in mRNA species from endotoxin-treated HMC. The appearance of 
single-spliced EIAV mRNA was delayed by endotoxin treatment. Together these 
results suggest that the inhibition of EIAV replication in endotoxin-treated HMC 
occurs during the transition from early to late stages in virus replication. 
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I n t r o d u c t i o n  
Equine infectious anemia virus (EIAV) is a member of the retrovirus 
subfamily, lentivirinae (Narayan and Clements, 1989; Issel and Coggins, 1979). 
Similar to other lentivinises, EIAV replicates in cells of the 
monocyte/macrophage lineage, has a complex genome organization, and causes 
an immunopathology (Chiu et a/.,1985; Gonda et a/.,1986; Issel and Coggins, 1979; 
Montagnier et a/.,1984; Montelaro et a/.,1988; Narayan and Clements, 1989; 
Rushlow et a/.,1986). Three types of clinical disease, described as acute, chronic 
or aclinical, have been observed in EIAV-infected horses (Narayan and Clements, 
1989; Issel and Coggins, 1979; Henson and McGuire, 1974; Squire, 1968). The acute 
type is characterized by viremia, hemorrhage, pyrexia, and a rapid onset of 
death. Horses which exhibit the chronic type of disease show clinical signs 
similar to the acute form, however they are less severe, include anemia, and 
occur in a cyclical manner. Horses with the aclinical type of disease, exhibit no 
apparent signs of disease. Both viral and cellular factors are likely to play a role 
in the clinical outcome of EIAV infection. 
A variety of cellular factors have been shown to be important in the 
regulation of lentivirus replication. For example, activation of cells with 
phorbol esters or certain cytokines stimulates gene expression of human 
immunodeficiency virus (HIV) (Chowdhury et a/.,1990; Poli et o/.,1990a; Folks et 
a/.,1987; Mellors et of.,1991; Poli et a/.,1990b; Israel et a/.,1989), simian 
immunodeficiency virus (Polacino et a/.,1993; Lairmore et a/.,1991), EIAV 
(Carvalho and Derse, 1993), visna virus (Shih et a/.,1992), and feline 
immunodeficiency virus (Sparger et a/., 1992). Many of these effects are 
54  
attributed to the activation of cellular transcription factors which directly or 
indirectly interact with enhancer sequences present in the viral long terminal 
repeat (LTR) resulting in increased viral gene expression (Liu et a/.,1992; 
Sparger et a/.,1992; Hess et a/.,1989; Shih et a/.,1992). Similarly, the EIAV LTR can 
be transcriptionally activated by treating transfected HeLa cells with a phorbol 
ester, and activation is mediated through an ets/PEA3 motif present in the LTR 
(Carvalho and Derse, 1993). 
Activation of cells has also been reported to inhibit lentivirus replication. 
HIV replication is inhibited by treatment of infected cells with a phorbol ester 
(Mufson et a/.,1992), interferon (IFN) (Kombluth et a/.,1990; Hartshorn et 
fl/.,1987; Meylan et a/.,1993; Ho et a/.,1985; Kombluth et a/.,1989; Faltynek et 
a/.,1988; Gendelman et a/.,1990a; Gendelman et a/.,1990b; Poli et a/.,1989; Shirazi 
and Pitha, 1992; Nakashima et a/.,1986), or bacterial lipopolysaccharide (LPS) 
(Kombluth et a/.,1989; Berstein et a/.,1991), The overall effects of cellular 
activation on lentivirus replication depends, in part, on the cell type used for in 
vitro studies. For example, cellular activation with a phorbol ester (Mufson et 
a/., 1992) or LPS (Kombluth et a/.,1989) inhibits HIV replication in primary 
human monocytes, but stimulates viral replication in chronically infected cell 
lines (Chowdhury et a/.,1990; Pomerantz et a/.,1990). Activation of primary 
human macrophages with IFN has been found to inhibit early stages in HIV 
replication (Kombluth et a/.,1990; Gendelman et a/.,1990b; Meylan et a/.,1993); 
while activation of various cell lines by the same method is thought to inhibit 
late stages in the virus life cycle (Poli et <z/.,1989; Gendelman et a/.,1990b). 
Previously, we observed that activation of primary horse macrophage 
cultures (HMC) with bacterial endotoxin resulted in decreased EIAV replication as 
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compared to unstimulated cells (Smith et a/.,1994). Although we found no 
correlation between levels of TNF-a and virus replication in activated 
macrophages, the inhibition of EIAV replication was most dramatic when basal 
levels of TNF-a were detected in HMC prior to infection (Smith et a/., 1994). This 
suggested that the activation state of the cell at the time of infection is important 
in the regulation of virus replication. Therefore, endotoxin treatment may 
inhibit an early stage in EIAV replication. In contrast, inhibition of HIV 
replication in normal human monocytes treated with LPS has been shown to 
occur at later stages of virus replication, including transcription (Berstein et 
a/., 1991) and virion release (Kombluth et a/.,1989). In the present study, we 
examined the mechanism of inhibition of EIAV replication in equine 
macrophages activated with bacterial endotoxin in vitro. 
Materials and Methods 
Animals and cells 
A donor pony housed at the Iowa State University Teaching Hospital and a 
horse from the Iowa State University Animal Science Department were used as 
blood donors. Whole blood was obtained by jugular venipuncture, and 
mononuclear leukocytes were banded by centrifugation at 750 x g on a 
discontinuous histopaque gradient (Carpenter and Chesebro, 1989). Cells were 
resuspended in Dulbecco's MEM (DMEM) containing 20% horse serum and 10% 
newborn calf serum (NCS), seeded at 2 x 10^ cells/cm^ in 6 well tissue culture 
plates, and allowed to adhere overnight at 37°C. The following day, nonadherent 
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cells were removed from the cultures by washing twice with Hank's buffered 
saline solution (HBSS) containing 2% fetal calf serum (PCS). Cells were 
maintained in DMEM containing 20% horse serum and 10% NCS. 
Equine dermal (ED) cells (ATCC #CCL57) were grown in DMEM 
supplemented with 20% PCS. 
Activation and infection of HMC 
HMC were activated at 24 hours by treatment with serially diluted bacterial 
endotoxin. Cells were washed with HBSS containing 2% PCS, and treated with 
fresh medium containing 0, 0.2, 1, or 5 M^g/ml Escherichia coli K235 endotoxin 
(Sigma Chemical Company, St. Louis, MO). Supernatant samples were collected 
from all wells immediately prior to, and four hours following HMC activation and 
tested for the presence of TNP-a using the L929 bioassay described below. At 48 
hours, HMC from each treatment group were infected with 1 x 10'* focus forming 
units of an avirulent strain of EIAV (MA-1) in the presence of 8 ^g/ml 
polybrene. The next day, cells were washed with HBSS containing 2% PCS to 
remove cell-free virus. HMC supernatant samples were collected at six days post­
infection, and tested for the presence of infectious virus as described below. 
Virus replication 
Infectious virus was quantitated using a focal immunoassay (PIA) which 
employed a chromogenic method of detection rather than the fluorogenic 
method described (Carpenter et a/.,1990). HMC supernatant samples were 
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clarified by low speed centrifugation, serially diluted ten-fold in DMEM 
containing polybrene (8 ng/ml) and added to cultures of ED cells. Five days post-
inoculation, ED cells were washed once with TNE buffer (10 mM Tris, 150 mM NaCI, 
1 mM EDTA, pH 7.5), fixed with 100% methanol for ten minutes, and washed again 
with TNE. The primary antibody, an EIAV convalescent horse serum (1:800), was 
added to the cells, and allowed to bind for at least one hour at room temperature. 
Unbound serum was removed by washing with TNE and the cells were incubated 
for 30 minutes at room temperature with the secondary antibody, horseradish 
peroxidase-conjugated goat anti-horse IgG polyclonal antibody (1:800) (Organon 
Teknika Corporation, Durham, NC). Unbound secondary antibody was removed as 
before, and AEC substrate, consisting of 0.2 mg/ml of 3-amino-9-ethylcarbazole 
and 0.01% hydrogen peroxide in 0.05 M sodium acetate solution (pH 5.0), was 
added. The substrate was allowed to react for ten minutes in the dark at room 
temperature, the cells were washed with tap water, and allowed to dry at room 
temperature. Foci of infected cells were counted using a dissecting microscope. 
TNF-a bioassay 
L929 cells (ATCC #CCL1 NCTC Clone 929) were seeded at 4 x 10^ cells per well 
in 96 well tissue culture plates in Eagle's Minimum Essential Medium (MEM) 
containing 10% horse serum and incubated for 24 hours at 37°C. HMC 
supernatant samples were diluted 1:5 and 1:50 in MEM containing 3 ng/ml 
actinomycin D, and 100 (il of each dilution was added to duplicate wells of L929 
cells. Cells were incubated overnight at 37°C, fixed with 50 |xl 10% phosphate 
buffered formalin, washed twice with 0.85% sodium chloride, and stained with a 
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gravity filtered solution of 0,2% crystal violet and 0.74% formaldehyde in distilled 
water. After washing the cells with tap water, plates were dried overnight at 
room temperature. The next day, 100 nl of a 1:1 solution of phosphate buffered 
saline:95% ethanol was added to each well of the plate, and the absorbance of the 
solution was read at 550 nm. As a positive control, ten-fold serial dilutions of 
recombinant murine TNF-a (rTNF-a) (Genzyme, Cambridge, MA) were added to 
duplicate wells of each test plate containing L929 cells. As negative controls, 
medium alone, and one Unit murine rTNF-a in the presence of anti-murine TNF-a 
antibody (Genzyme, Cambridge, MA) were added to duplicate wells of each test 
plate. 
Isolation and amplification of proviral DNA 
EIAV proviral sequences were amplified by PCR to determine the effect of 
macrophage activation on reverse transcription. Total cellular DNA was isolated 
at six hours, 18 hours, 43 hours, and six days post-infection from one well each of 
infected and non-infected HMC treated with each dilution of bacterial endotoxin. 
Cell lysates were prepared by SDS-proteinase K digestion, and DNA was extracted 
with phenol and chloroform/isoamyl alcohol, and precipitated with ethanol. The 
quality and quantity of DNA in each sample was determined by electrophoresis in 
a 1% agarose gel and the optical density at 260 nm (Sambrook et a/., 1989), and the 
amount of DNA used for each PCR reaction was normalized based on the number 
of cells from which each sample was originally isolated (4.5 x 10^ cells/reaction). 
EIAV early and late proviral transcripts were amplified using synthetic 
oligonucleotide primers based on published sequences (Table 1). Standard 
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amplification conditions consisted of 35 cycles of primer annealing at 50°C for 1 
min, primer extension at 72°C for 2 min, and denaturation at 94°C for 1 min in an 
automated thermocycler (Perkin Elmer Cetus, Norwalk, CT). Positive and negative 
controls used for each PCR reaction included a plasmid containing proviral MA-1 
DNA and distilled water. For analysis, 15 ^1 of the PCR products was 
electrophoresed in 2% agarose, transfered overnight to Hybond nylon 
membranes (Boehringer Mannheim Biochemicals) by an alkaline transfer 
technique, and hybridized with EIAV LTR-specific probes radiolabeled with 
with the random hexamer primer technique (Carpenter et a/., 1991). To ensure 
that comparable amounts of input DNA were used in each experiment, p-actin 
sequences were co-amplified as an internal control, p-actin-specific primers 
were designed based on sequences obtained from conserved regions of p-actin 
cDNA, and were kindly provided by Dr. Michael Murtaugh from the University of 
Minnesota (Table 1). All blots were stripped and probed with a p-actin-specific 
probe radiolabelled with ^^P using the random hexamer primer technique. 
Isolation and amplification of viral mRNA species 
The effect of macrophage activation on EIAV transcription was determined 
using RT-PCR to amplify EIAV cDNA sequences from different viral mRNA 
species. HMC were established, treated with bacterial endotoxin, and infected 
with EIAV as described above. At six hours, 18 hours, 43 hours and six days 
following infection, total cellular RNA was isolated from triplicate wells using 
guanidinium thiocyanate (Stratagene, La Jolla, CA) and phenol and 
choloroform/isoamyl alcohol extraction. RNA was precipitated from each sample 
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with ethanol, pooled, and quantitated using a commercially available kit 
(Invitrogen Corporation, San Diego, CA). EIAV mRNA was reverse transcribed 
into DNA with random hexamer primers, and the subsequent cDNA produced was 
amplified by PCR using splice-specific primers (Table 1) with the GeneAmp Kit 
(Perkin Elmer-Cetus, Norwalk, CT). EIAV-specific primers were designed based 
on published sequences (Kawakami et a/..1987). The amount of RNA used for each 
RT-PCR reaction was normalized according to the number of cells from which the 
RNA was originally isolated (9 x 10® cells/reaction). Control RNA provided in the 
RT-PCR kit and distilled water were used as controls for each experiment. IS |il of 
the RT-PCR reaction products was electrophoresed in 2% agarose, transfered 
overnight to nylon membranes (Boehringer Mannheim Biochemicals), and 
hybridized to probes specific for each corresponding amplified sequence as 
described above (Figure 2). In addition, each sample was co-amplified using 
primers specific for p-actin cDNA, and all blots were stripped and reprobed with a 
P-actin-specific probe. 
R e s u l t s  
Dose-dependent relationship of endotoxin treatment and EIAV replication 
In previous studies we observed that EIAV replication was inhibited in 
endotoxin-treated HMC, and that inhibition of viral replication was more 
dramatic when basal levels of TNF-a were detected at the time of infection (Smith 
et a/.,1994). Since these results indicated that the inhibition of virus replication 
may occur during early stages after infection, we examined the effects of 
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endotoxin treatment on virus replication in HMC activated prior to infection. 
HMC were established from a donor pony, treated with serial dilutions of bacterial 
endotoxin at 24 hours, and infected with EIAV at 48 hours. HMC supernatant 
samples were collected and assayed for levels of TNF-a and titers of infectious 
virus. As expected, a dose-dependent relationship was observed between 
endotoxin treatment and TNF-a production: HMC treated with high levels of 
endotoxin produced more TNF-a than HMC treated with less endotoxin (Figure 1). 
A dose-dependent relationship also occurred between the amount of endotoxin 
used to treat HMC and EIAV replication. HMC treated with high levels of 
endotoxin were less permissive for EIAV replication than HMC treated with lower 
levels of endotoxin. A similar inverse relationship occurred between units of 
TNF-a in the HMC supernatant at the time of infection and permissiveness for 
EIAV replication (Figure 1). Results from these experiments suggested that 
activation of HMC may affect virus replication early after infection. 
Effects of endotoxin treatment on EIAV reverse transcription 
Results from the above experiments demonstrated a decrease in EIAV 
replication when HMC were treated with bacterial endotoxin prior to infection. 
This suggests that the inhibitory effect of endotoxin treatment may occur early 
after infection. Therefore, we examined the effects of endotoxin treatment on 
reverse transcription, an event which occurs early in life cycle of the virus. 
Due to the pattern of reverse transcription, early and late proviral transcripts 
can be analyzed by Southern blot analysis after PCR amplification using specific 
oligonucleotide primers (Figure 2). For these experiments, HMC were established 
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from a donor pony, treated with serially diluted bacterial endotoxin, and infected 
with EIAV. Total cellular DNA was isolated from cells in each treatment group, 
and EIAV LTR-specific and p-actin-specific sequences were co-amplifîed by PGR. 
Early transcripts of proviral DNA were observed six hours following infection 
(data not shown), while late transcripts could not be detected until 43 hours post­
infection (Figure 3). Regardless of HMC treatment, there were no significant 
differences in either the quality or quantity of early or late proviral transcripts 
until six days after infection (Figure 3). At six days post infection, proviral 
transcripts detected from HMC treated with bacterial endotoxin appeared to 
decrease with increasing amounts of endotoxin (Figure 3). However, at all time 
points following infection, variable amounts of p-actin DNA were detected which 
appeared to be independent of both time and endotoxin treatment (Figure 3). 
Based on these results, it is difficult to determine if the decrease in proviral DNA 
which was detected at six days post-infection is a direct result of an endotoxin 
treatment effect. Together, the data indicate that reverse transcription and prior 
events in the virus life cycle, such as viral binding, entry and uncoating, are not 
significantly affected by treatment of HMC with bacterial endotoxin. 
Detection of EIAV mRNA transcripts from HMC 
Alternative splicing following transcription is necessary for the 
expression of different lentiviral genes: the gag and pol genes are expressed 
from a full-length transcript; the env gene from a singly spliced transcript; and 
the regulatory genes, tat and rev, from multiply spliced transcripts (Beisel et 
a/.,1993; Noiman et a/.,1990; Stephens et a/.,1990; Schiltz et a/.,1992). Synthetic 
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oligonucleotide primers (Table 1) were designed to amplify splice-specific 
sequences from each viral mRNA using RT-PCR (Figure 2). To establish that 
specific EIAV mRNAs could be detected by Southern blot analysis after being 
reverse transcribed into cDNA and amplified by PGR, and to determine the 
optimal time for RNA isolation after infection, HMC were established from a horse 
housed at the Department of Animal Science, Iowa State University. Cultures 
were infected at 48 hours with EIAV, and RNA was isolated from each culture at 
16, 24, 40, 64 and 89 hours post infection and amplified by RT-PCR. Full-length 
mRNA was detected at all time points examined (data not shown), although 
multiply spliced transcripts could not be detected until at least 24 hours following 
infection (Figure 4 A). Therefore, the viral genomic RNA which entered the cell 
during infection was indistinguishable from newly transcribed full-length 
mRNA. 
Based on splicing patterns previously described (Noiman et a/.,1990; 
Stephens et a/.,1990; Schiltz et a/.,1992), a triple-spliced transcript may be 
produced which consists of four exons and should be amplified using both primer 
pairs, 8 and 9 (Figure 2). The first detectable multiply spliced transcript is 
apparently triply spliced and was detected using primer pair 9 (Figure 4A) at 24 
hours. This transcript was detected at relatively high levels by 40 hours post­
infection and was the predominant transcript detected at all time points. 
However, this transcript was not detected using primer pair 8, indicating that it 
is likely produced using an alternate splice acceptor in exon 3 which differs 
from that previously described. Two bands were observed after RT-PCR using 
primer pair 8, a 483 bp fragment amplified from triple-spliced mRNA and a 645 
bp fragment amplified from single-spliced mRNA (Figure 4 A). Both fragments 
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are consistent in size with the expected products based on previously described 
splicing patterns. However, this previously described triply spliced transcript 
containing the upstream splice site was not detected until 89 hours after 
infection, and was less abundant than that detected with primer pair 9 (Figure 
4A). It is possible that the use of downstream alternate splice acceptor sites would 
affect the expression and/or function of EIAV Rev encoded by these mRNAs. 
However, singly spliced transcripts were detected as early as 40 hours following 
infection using primer pair S (Figure 4 A) suggesting that the transcript detected 
by primer pair 9 encodes a functional Rev. 
To further examine splicing patterns of multiply spliced viral mRNAs, 5' 
and 3' oligonucleotide primers were used to amplify sequences spanning all 
spliced regions (Figure 2). RNA samples isolated above were converted to cDNA 
and amplified using RT-PCR with primer pair 10 (Table 1). The first detectable 
multiply spliced mRNA was observed at 24 hours post-infection (Figure 4 B, lane 
1). However, this fragment is smaller in size than the fragments expected based 
on previously reported splicing patterns. At 40 hours, a 730 bp fragment was 
detected which is consistent with the predicted size fragment amplified from the 
doubly spliced transcript which encodes Tat. By 64 and 89 hours, a 589 bp 
fragment which was likely amplified from the Tat/Rev transcript could be 
detected, as well as the Tat transcript and other smaller transcripts. The results 
from these experiments indicate that in infected HMC multiply spliced EIAV 
mRNAs are produced from splicing patterns which differ from those previously 
described. 
65  
Effects of macrophage activation on the production of EIAV mRNAs 
To examine the effects of endotoxin treatment on the transcription of EIAV 
mRNA, HMC were established from a donor pony, treated with serially diluted 
bacterial endotoxin at 24 hours, and infected with EIAV at 48 hours. RNA was 
isolated from HMC at six hours, 18 hours, 43 hours, and six days following 
infection, and RT-PCR was used to produce and amplify cDNA sequences from 
each viral mRNA (Figure 2). Co-amplification of p-actin sequences by RT-PCR 
indicated that comparable amounts of RNA were present at 43 hours (Figure 5). 
At six days, however, a dose-dependent response was observed between endotoxin 
treatment and the detection of P-actin transcripts (Figure 5). This suggests that 
while endotoxin treatment has no immediate affects on transcription, cell 
metabolism appears to be decreased at six days post-infection. 
During lentivirus replication, multiply spliced mRNAs which encode the 
regulatory proteins. Tat and Rev, are the predominant transcripts early after 
infection, while full-length and singly spliced transcripts encoding the 
structural proteins. Gag, Pol, and Env, are predominant later in an infection (Kim 
et a/.,1989). Triple-spliced mRNA could be detected as early as six hours post­
infection (data not shown), and at early time points following infection, 
endotoxin treatment appeared to have no effect on transcription of this 
transcript (Figure 5). Again, this transcript was detectable only when using 
primer pair 9 and remained the predominant transcript detected at all time 
points after infection. Using primer pair 8, the predicted singly and triply 
spliced mRNAs were not detectable until six days post-infection (Figure 5). These 
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results suggest that an alternate splice acceptor for exon 3 is utilized in infected 
HMC to generate a triply spliced transcript. 
Similar to earlier experiments, results from these experiments suggest that 
in primary HMC, alternative splicing patterns are being utilized which differ 
from those previously described (Figure 2). To investigate this possibility, RNA 
samples were amplified by RT-PCR using primers 10a and 10b, which span the 
splicing regions (Figure 2). Variation was observed in both the size and number 
of transcripts, as well as the predominant transcript species which were detected 
at each time point following infection (Figure 6). Transcript variation appeared 
to be dependent on both time and endotoxin treatment. At 18 hours post­
infection multiple bands which ranged in size from approximately 500 bases to 
1200 bases, were amplified from HMC treated with S ng/ml of bacterial endotoxin 
while no transcripts were detected in untreated HMC at the same time point. 
After 43 hours, two bands were observed from both endotoxin- and non-treated 
HMC samples which appeared to be approximately 600 and 700 bases each. These 
bands are consistent with the expected products of 589 bp and 730 bp amplified 
from the predicted triple-spliced Tat/Rev and double-spliced Tat transcripts, 
respectively. By six days, an additional transcript of approximately 500 bases was 
detected in endotoxin treated HMC, but not in untreated HMC. Interestingly, 
doubly spliced transcripts were not detected until six days post-infection using 
primer pair 7 (data not shown). These results indicate that transcripts which 
vary in size are being produced in infected HMC by alternative splicing patterns 
which have not been previously described. Also, endotoxin treatment results in 
the utilization of splicing patterns which differ from those observed in untreated 
HMC. 
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Full-length mRNA, likely to include genomic RNA carried into the cell 
during infection, was detected at six hours post-infection from samples of 
endotoxin-treated and untreated HMC (data not shown). No quatitative or 
qualitative differences were observed in the production of full-length 
transcripts at any of the time points sampled after infection. However, from 
these experiments viral genomic RNA could not be differentiated from newly 
transcribed full-length mRNA. Using primer pair 8, singly spliced transcripts 
were not detected until six days post-infection from either endotoxin-treated and 
untreated HMC RNA samples (Figure 5). When the PCR was extended to 45 cycles, 
single-spliced mRNA could be detected with primer pair S at 43 hours post­
infection from untreated HMC, but remained undetectable until six days after 
infection from endotoxin-treated HMC (Figure 7 A). Interestingly, two bands of 
similar size were amplified using this primer pair. For increased sensitivity in 
the detection of singly spliced transcripts, nested PCR was utilized with primer 
pair 5, after amplification by RT-PCR with primer pair 6 (Figure 2). Using this 
method, the predicted single-spliced mRNA was detected as early as 18 hours 
following infection in non-treated HMC as well as endotoxin-treated HMC, 
although, overexposure was required to detect this band in endotoxin-treated 
HMC (Figure 7 B, arrow). Quantitative differences were also observed at 43 hours 
post-infection between endotoxin treated and untreated HMC, but transcripts 
appeared equivalent by six days after infection (Figure 7 B). The results from 
these experiments indicate that the activation of HMC using bacterial endotoxin 
is associated with a delay in the appearance of single-spliced mRNA suggesting 
that endotoxin treatment may inhibit Rev function early after infection. 
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D i s c u s s i o n  
Cellular activation has been shown to affect the replication of lentiviruses 
(Chowdhury et a/.,1990; Poli et û/.,1990a; Folks et a/.,1987; Mellors et a/.,1991; Poli et 
a/.,1990b; Israel et a/.,1989; Kombluth et a/.,1990; Hartshorn et a/.,1987; Meylan et 
al.,1993; Ho et a/.,1985; Kombluth et of.,1989; Faltynek et a/.,1988; Gendelman et 
a/., 1990a; Gendelman et a/..1990b; Poli et a/.,1989; Shirazi and Pitha, 1992; 
Nakashima et a/.,1986; Berstein et a/.,1991). Previously we have shown that 
activation of primary HMC with bacterial endotoxin results inhibition of EIAV 
replication (Smith et a/., 1994). The current experiments were designed to more 
fully examine the effect of endotoxin treatment on EIAV replication in primary 
HMC. Endotoxin treatment had no apparent effect on reverse transcription and 
earlier events in the virus life cycle, but resulted in a delay in the appearance of 
singly spliced mRNA encoding viral structural proteins. In addition, splicing 
patterns in HMC differed from those previously described, and varied with 
endotoxin treatment. These results suggest that the inhibition of EIAV 
replication in endotoxin-treated HMC occurs during the transition from early to 
late stages in virus life cycle. 
HMC were treated with serially diluted bacterial endotoxin prior to 
infection in order to more clearly define the relationships between endotoxin 
treatment, TNF-a production, and virus replication. EIAV replication was 
inhibited in a dose dependent manner in HMC treated with bacterial endotoxin. 
Also, a dose dependent relationship was observed between endotoxin treatment 
and TNF-a production by HMC. We previously found that TNF-a per se had no 
effect on EIAV replication (Smith et a/.,1994). Therefore, the inhibition of virus 
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replication is likely due to cellular activation events stimulated by endotoxin 
treatment, rather than the direct effects of TNF-a on virus replication. Based on 
these results, it appears that EIAV replication may be inhibited early after 
infection by cellular factors which are present in activated macrophages. 
Both bacterial endotoxin (Smith and Wagner, 1966) and TNF-a (Kohase et 
a/., 1986) have been reported to induce interferon (IFN) production by 
macrophages, and IFN has been reported to have antiviral effects on many types 
of viruses, including retroviruses (Chatterjee and Hunter, 1987; Pitha et a/.,1976; 
Kombluth et <i/.,1990; Hartshorn et a/.,1987; Meylan et a/.,1993; Ho et a/.,1985; 
Kombluth et a/.,1989; Faltynek et a/.,1988; Gendelman et a/.,1990a; Gendelman et 
a/.,1990b; Poli et a/.,1989; Shirazi and Pitha, 1992; Nakashima et a/.,1986; Zink and 
Narayan, 1989). Treatment of HIV-infected normal human macrophages with IFN 
resulted in decreased detection of proviral DNA, indicating that virus replication 
was inhibited early after infection (Kombluth et a/.,1990; Gendelman et a/.,1990b; 
Meylan et a/.,1993). Although it has not been shown that IFN can directly inhibit 
EIAV replication, bacterial endotoxin may exert indirect antiviral effects on EIAV 
mediated by IFN which inihibit early stages in virus replication. 
The synthesis of proviral DNA by reverse transcription is an event which 
occurs early after infection. To examine the effects of endotoxin treatment on 
the early stages of EIAV replication, specific sequences of early and late proviral 
transcripts were amplified by PCR. Activation of HMC with bacterial endotoxin 
appeared to have no effect on EIAV reverse transcription early after infection, 
suggesting that virus replication is not inhibited at the stages of entry, 
uncoating, or reverse transcription. However, decreased proviral DNA was 
detected at six days post-infection, which may be the result of inhibition 
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throughout multiple rounds of virus replication. It has been reported that LPS 
inhibits HIV replication at multiple points in the virus life cycle, including 
virion release (Kombluth et a/.,1989) and transcription (Berstein et a/.,1991). 
Also, when decreased levels of viral gene expression were observed with 
endotoxin treatment, the secretion of IFN from monocyte-derived macrophages 
was not detected, indicating the inhibition of HIV replication was not mediated by 
IFN (Kombluth et a/.,1989). Others have shown that an RNA-binding protein 
induced by IFN inhibits Rev-dependent post transcriptional steps in HIV gene 
expression (Constantoulakis et a/.,1993). Results from our experiments 
demonstrate that the early events of EIAV replication are not inhibited by 
treatment with bacterial endotoxin. It is possible that endotoxin treatment of 
primary HMC induces the production of IFN which inhibits EIAV replication via 
mechanisms which affect intermediate or late events in the virus life cycle, 
rather than early events. Alternately, the inhibition of virus replication in HMC 
activated with bacterial endotoxin may not involve IFN. 
Endotoxin-treatment appeared to have no effect on the early events of 
virus replication, therefore RT-PCR was used to examine the effects of endotoxin 
on the transcription of EIAV mRNAs. Results indicated that the appearance of 
single-spliced EIAV mRNA was delayed in endotoxin-treated HMC, while the 
production of other viral transcripts appeared to be unaffected by endotoxin 
treatment. Down-regulation of the HIV LTR has been shown in human 
monocyte-derived macrophages activated with LPS (Berstein et a/.,1991). 
However, it is unlikely that the delay we observed in the appearance of singly 
spliced transcripts is due to transcriptional down-regulation since the 
production of multiply spliced EIAV transcripts was not quantitatively affected 
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by endotoxin treatment. The delay may be the result of alterations in splicing 
patterns which inhibit the formation of singly spliced EIAV transcripts and/or 
inhibition of functional Rev. Cellular regulation of splicing events has not been 
clearly defîned, but is thought to involve protein-RNA and protein-protein 
interactions between both specialized and general splicing factors as well as 
specific pre-mRNAs (Maniatis, 1991; Latchman, 1990; Smith et a/.,1989; Nadal-
Ginard et a/., 1991). Splicing factor 2 and alternative splicing factor are two 
cellular factors which bind nonspecifically to RNA and are required for the 
assembly and stablization of spliceosomes to promote the annealing of 
complementary RNA (Maniatis, 1991). It has been hypothesized that cell-specific 
differences in the concentrations or activities of these general splicing factors 
may regulate alternative splicing (Maniatis, 1991; Latchman, 1990; Smith et 
a/.,1989; Nadal-Ginard et a/.,1991). In addition, the viral protein Rev has been 
reported to increase the stability of unspliced HIV mRNA (Felber et a/.,1989), to 
specifically inhibit the splicing of pre-mRNAs containing an Rev response 
element (RRE) (Kjems et a/.,1991), and to affect the transport of RRE-containing 
mRNAs from the nucleus to the cytoplasm (Felber et a/.,1989). The inhibition of 
splicing occurs during a step in the assembly of splicing complexes, during 
which the basic domain of Rev blocks the entry of U4, US, and U6 small nuclear 
RNAs into the spliceosome (Kjems and Sharp, 1993). Therefore, Rev prevents the 
formation of a functional spliceosome (Kjems and Sharp, 1993; Kjems et a/.,1991). 
Further work is required to determine if cellular splicing factors and/or Rev are 
involved in the delayed appearance of EIAV singly spliced transcripts in 
endotoxin-treated HMC. 
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The presence of multiple, alternately spliced viral transcripts was 
observed in HMC, regardless of treatment. The particular splicing patterns 
which occurred appeared to be more dependent on time rather than endotoxin 
treatment. Utilization of alternative splice acceptors has also been shown to 
occur with HIV, and are responsible for the excision of the major S' intron of 
HIV. Utilization of two of these new splice acceptors, located IS and 9 nucleotides 
upstream from the rev start codon, creates transcripts suitable for rev expression 
(Guatelli et a/., 1990). Others have shown that mutations in constitutive splice 
sites of HIV results in the activation of new cryptic sites. Utilization of these new 
cryptic splice sites produces marked changes in the pool of viral mRNAs, 
indicating a possible mechanism for the regulation of HIV protein expression 
and viral infectivity. 
Three alternatively spliced EIAV transcripts have recently been described 
which are thought to encode Rev (Rosin-Arbesfeld et al.,1993). Two of these 
transcripts are made up of four exons; one is identical to that shown in figure 2, 
and the other is hypothesized to utilize a splice acceptor at base 5210, rather than 
5135 in the second exon. The latter of these cannot encode a functional Tat 
protein since the splice acceptor is located within the tat open reading frame, SI. 
The third alternatively spliced transcript described consists only of the second 
codon of S3 which encodes Rev, splicing from base 459 to 7235. Interestingly, the 
predicted triple-spliced mRNA encoding a Tat/Rev bicistronic mRNA could be 
detected using primer pairs 9 and 10, but not primer pair 8. This suggests that an 
alternate splice acceptor may be utilized in exon 3. The effect of alternate splice 
acceptor usage on the expression of functional Rev was not determined, however, 
it is interesting that one predominant effect of endotoxin treatment, a delay in 
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single-spliced mRNA, is consistent with a decreased Rev function. Structural and 
functional analysis of alternately spliced transcripts will be required to fully 
assess the mechanisms of endotoxin treatment on Rev function in activated HMC, 
and to determine the significance of these alternative splicing events in the 
replication of EIAV and viral pathogenesis. 
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Figure 1. TNF-a production and EIAV replication in HMC treated with varying 
concentrations of bacterial endotoxin. HMC established from a donor pony were 
treated at 24 hours with 0, 0.2, 1, S, or 25 pg/ml of bacterial endotoxin, then 
infected with EIAV 24 hours later. Levels of TNF-a (light bars) in HMC 
supernatant samples collected immediately prior to infection were determined 
using the L929 bioassay described in the text. The FIA, also described in the text, 
was used to quantitate infectious EIAV (dark bars) in HMC supernatant samples 
collected six days post-infection. Each bar represents the mean of data obtained 
from duplicate wells. 
Figure 2. Schematic represention of EIAV proviral DNA and mRNA. Arrows 
represent the location of oligonucleotide primers (see Table 1) used for PCR and 
RT-PCR amplification of specific proviral DNA and mRNA sequences, 
respectively. (A) EIAV proviral DNA. Reverse transcription initiates at the 
primer binding site (*) and proceeds in a 5' to 3' direction as indicated. Early 
proviral transcripts were detected using primers la and lb, while late transcripts 
were detected using primers 2a and 2b. (B) Reported splicing patterns utilized to 
generate predominant EIAV mRNA transcripts and potentially encoded proteins. 
(C) Striped bars represent probes used to detect specific sequences amplified by 
PCR and RT-PCR. 
Figure 3. Detection of early and late EIAV proviral transcripts using PCR. HMC 
were established from a donor pony, treated with 0, 0.2, 1, and S |ig/ml of 
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bacterial endotoxin at 24 hours, and infected with EIAV at 48 hours. At 18 hours, 
43 hours, and six days post-infection, total cellular DNA was isolated from each 
culture, and EIAV specific proviral sequences were amplified with PCR using 
LTR-specific primers designed to detect proviral DNA formed during early and 
late reverse transcription (see Figure 2). Total cellular DNA was isolated from 
non-infected HMC at six days post-infection and used as a negative control for 
each PCR reaction (6 d NI). PCR products were electrophoresed in 2% agarose 
gels, transfered to nylon, and hybridized with an EIAV LTR-specific probe, p-
actin DNA sequences were co-amplified in each corresponding PCR reaction, and 
all blots were stripped and re-probed using a p-actin-specific probe. 
Figure 4. Detection of EIAV mRNA transcripts and alternative splicing events 
using RT-PCR. HMC were infected with EIAV at 48 hours, and total cellular RNA 
was isolated at 16, 24, 40, 64, and 89 hours post-infection. Oligonucleotide primers 
were used to amplify sequences from specific EIAV-transcripts by RT-PCR (see 
Figure 2). Reaction products were electrophoresed in 2% agarose gels, transfered 
to nylon, and hybridized with sequence-specific EIAV probes. (A) Single-spliced 
mRNA (ss mRNA) using primer pairs S and 8 and triple-spliced mRNA using 
primer pairs 8 (ts mRNA 8) and 9 (ts mRNA 9). (B) Transcripts detected following 
amplification by RT-PCR using primer pair 10. The sizes of selected molecular 
weight markers are located at the left. 
Figure 5. Effects of bacterial endotoxin treatment on the transcription of EIAV 
mRNAs. HMC established from a donor pony were treated with serially diluted 
bacterial endotoxin (0, 0.2, 1, and S ^ig/ml) at 24 hours, and infected with EIAV at 
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48 hours. Total cellular RNA was isolated at 43 hours and six days post-infection. 
Primer pairs 8 and 9 were used to amplify triple-spliced mRNAs (ts mRNA 8 and ts 
mRNA 9, respecitively)(see fîgure 2). Singly spliced transcripts (ss mRNA) are 
also amplifîed using primer pair 8. p-actin mRNA sequences were co-amplified 
in each RT-PCR reaction using specific primers (see table 1). Reaction products 
were electrophoresed in 2% agarose, transfered to nylon, and hybridized with 
EIAV-specific probes. Blots were stripped and rehybridized with a P-actin-
specific probe. 
Figure 6. Detection of multiply spliced EIAV transcripts. HMC established from a 
donor pony were treated with 0 and S ^g/ml of bacterial endotoxin at 24 hours 
and infected with EIAV at 48 hours. At 18 hours, 43 hours and six days post­
infection, total cellular RNA was isolated from HMC, and sequences spanning all 
spliced regions were amplified by RT/PCR using primer pair 10 (see Figure 2). 
Reaction products were electrophoresed in 2% agarose gels, transfered to nylon, 
and hybridized with EIAV-specific probes. The sizes of selected molecular weight 
markers are located at the left. 
Figure 7. Detection of singly spliced EIAV transcripts. HMC established from a 
donor pony were treated with 0 and S |xg/ml of bacterial endotoxin at 24 hours 
and infected with EIAV at 48 hours. Total cellular RNA was isolated from HMC at 
18 hours, 43 hours and six days following infection. (A) Singly spliced 
transcripts (ss mRNA) were amplified using RT-PCR extended to 45 cycles with 
primer pairs S. (B) For nested RT-PCR, singly spliced trascripts were amplified 
first with primer pair 6, then reaction products were further amplified using 
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primer pair 5. Products were electrophoresed in 2% agarose gels, transfered to 
nylon, and hybridized with sequence specific probes. The sizes of selected 
molecular weight markers are located at the right. Arrow indicates the location 
of a single band which can be observed 18 hours after infection from endotoxin-
treated (5 ^g/ml) HMC when the blot is overexposed 
Table 1. Oligonucleotide primers used for 
Primer Location Sequence 
1 (a) 1-20 TGTGGGGrmTATGAGGGG 
(b) 299-320 GTAGGATCrOGAACAGACAAAC 
2 (ay: 228-246 TGAGKXXTTCrCTGCTAG 
(b) 714-733 TGGAGCœCATCnTACAGC 
3 (a) 305-326 OGirOGAGATCCTACAGTrGG 
(b) 714-733 TGGAGGCCCATCnTACAGC 
4(a) 5078-5097 GCrGTACXZATTAAOCAGGAC 
(b) 5450-5468 TTCcnTOcrroGAiiiciiuc 
5 (a) 305-326 CIGTIXXiAGATCCTACAGITGG 
(b) 5552-5571 OCAGTAGrTOCrGCTAAGCA 
6(a) 305-326 CTCnrOGAGATCriACAGnGG 
(b) 5584-5603 OCrCAACAOGTACAGAGrrA 
7(a) 305-326 CKnTa3AGATCCrACAGTIGG 
(b) 5231-5250 anTirncGATiGOcrrcAG 
8(a) 305-326 CrcnCGAGATCCTACAGrrGG 
(b) 5450-5468 TiGcrrocrroGAri'CiiiiC 
9(a) 5514-5533 GAAGAAATGACTGGTGGAAA 
(b) 7552-7571 ACXDOGITCITGIGCTOGTIG 
amplification of viral" and p-actin^ sequences 
Size Amplified Product 
320 bp U3-U5 proviral DNA 
506 bp R-GAG proviral DNA 
429 bp unspliced RNA 
391 bp unspliced RNA 
589 bp single-spliced RNA 
921 bp single-spliced RNA 
268 bp single- and double-spliced RNA 
483 and 645 bp triple- and single-spliced RNA^ 
359 bp triple-spliced RNA 
Table 1. (continued) 
Primer Location Sequence Size Amplified Product 
10 (a) 305-326 CTCITOGAGATCCTACAGTrGG variable multiple-spliced RNA 
(b) 7552-7571 AGOOGTTCriGICOOCîITG 
11 (a) NA« ATGTITGAGACCITCAACAC 760 bp cellular P-actin 
(b) NA TCATœACATCTGCTGGAAGG 
Oligonucleotide primers specific for EIAV are numbered based on published sequences (Kawakami et al., 1987) 
obtained from Genbank (Accession numbers M16S7S, Ml 1337, K03334, and M1485S). 
^ Oligonucleotide primers specific for p-actin were provided by Dr. Michael Murtaugh at the University of NGnnesota. 
c Base number 245, A, differs from the published sequence of G. 
^ Expected products are 483 and 645 bp from triple- and single-spliced mRNA, respectively 
^ Primers were designed based on consensus sequences, therefore location is not applicable (NA). 
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GENERAL œNCLUSION 
The regulation of lentivirus replication is complex, involving both host 
and viral factors [83]. Although several hypotheses have been made, the specific 
mechanisms which determine the pathogenesis of lentiviral infections and 
result in the establishment of persistent infections are still unknown. The 
overall goal of this research was to characterize the effect of host cell variability 
on EIAV replication in vitro. 
Permissiveness for equine infectious anemia virus (EIAV) was shown to 
vary significantly among horses. Intrinsic differences among horses at the 
cellular level are believed to be involved in the regulation of virus replication, 
since the variation among horses was not correlated with age, breed, sex, or 
previous medical history. These cellular differences are likely to determine the 
permissiveness for EIAV in vivo and may affect the outcome of clinical disease in 
an infected animal. 
In addition, activation of primary horse macrophage cultures (HMC) with 
bacterial endotoxin resulted in significantly decreased replication of EIAV. 
Reverse transcription of proviral DNA early after infection was not affected by 
endotoxin treatment. Also, no quantitative differences were observed in full-
length or multiply-spliced mRNAs early after infection. However, endotoxin 
treatment delayed the appearance of singly spliced EIAV transcripts which 
encode viral structural proteins. In addition, variable splicing patterns 
dependent on both time and dose of endotoxin were observed in transcripts from 
endotoxin-treated HMC. It was not determined if the use of alternate splice 
acceptor sites effects Rev function, however, one effect of endotoxin treatment 
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was a delay in the appearance of single spliced mRNA, a phenotype which is 
consistent with decreased Rev function. Therefore, Rev transcription from 
alternately spliced mRNA may be less biologically active than wild-type Rev. 
Another possibility is that endotoxin treatment induces factors which 
competitively inhibit Rev function similar to that described for HIV [24]. Future 
experiments involving sequence analysis and functional characterization of 
alternatively spliced transcripts present in untreated and endotoxin-treated HMC 
will identify their role in EIAV replication. Together, the results from these 
experiments suggest that the inhibition of EIAV replication in endotoxin-treated 
HMC occurs during the transition from early to late stages in virus replication. 
The results from this dissertation research support our hypothesis that 
biological variation in cellular factors controls EIAV replication early after 
infection. Further work is needed to identify specific cellular factors which 
regulate EIAV replication and determine their effects on the outcome of clinical 
disease in EIAV-infected animals. Identification of these cellular factors may 
lead to the design of therapeutic agents useful for treatment of lentiviral 
infections in vivo. 
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APPENDIX A. DEVELOPMENT OF AN EQUINE MACROPHAGE CELL LINE 
Equine infectious anemia virus (EIAV) is a lentivirus and replicates in 
cells of the monocyte/macrophage lineage [45,83]. Both viral and host factors 
affect EIAV replication in vitro, and clinical disease in vivo [1,5,50,55,56,89,100]. 
Currently, equine monocytic cell lines are not available to examine virus-host 
interactions in vitro, therefore, primary cultures must be established from blood. 
This procedure is tedious and technically difficult. In order to better define the 
regulation of EIAV replication in vitro and to investigate its role in the 
pathogenesis of disease, it was desirable to develop an equine 
monocyte/macrophage cell line. 
The establishment of a cell line requires the transformation of cells which 
normally have a limited life span into immortalized cells capable of continuous 
growth [65]. One method of inducing cell transformation involves the expression 
of viral oncogenes capable of immortalizing cells. The SV40 large T antigen gene 
is an example of an oncogene encoded by simian virus 40 which is commonly 
used for transformation of many types of cells [17]. Foreign DNA containing the 
gene encoding the SV40 large T antigen can be introduced into cells in vitro 
using transfection. For these experiments we attempted to transform equine 
macrophages in vitro by transfecting plasmid DNA carrying the SV40 large T 
antigen into primary macrophage cultures. 
Whole blood was collected from a donor pony by jugular venipuncture, 
and the mononuclear leukocytes were isolated by centrifugation at 750 x g on a 
discontinuous histopaque gradient. Cells were washed with Hank's buffered 
saline solution (HBSS) containing 2% fetal calf serum (PCS), resuspended in 
103 
Dulbecco's MEM containing 20% horse serum and 10% newborn calf serum, and 
seeded at 2 x 10^ cells/cm^ in 60 mm tissue culture dishes. After 24 hours, 
cultures were washed to remove non-adherent cells and fresh media was added to 
each dish, At 48 hours, cultures were washed twice with HBSS containing 2% PCS, 
and transfected by calcium phosphate mediated precipitation with 10, 20 and 40 
^g of either the SV3Neo plasmid (ATCC #37150) or the SV5Neo plasmid (ATCC 
#37151). Both SVNeo plasmids contain the SV40 large T antigen gene which is 
driven by the SV40 late promoter as well as the neomycin resistance gene for 
selection in mammalian cells. We had previously observed that primary equine 
macrophage cultures have a life span limited to approximately seven to 14 days, 
and transfonned cells were selected based on prolonged cell growth beyond three 
weeks after establishment of the culture. 
Using this method we were unable to successfully establish an equine 
macrophage cell line, however we did observe extended viability with cells that 
were transfected with 10 ^g of SV3Neo plasmid DNA (Table 1). These cells 
remained viable for 73 days following transfection and were subcultured twice 
during that period of time. Despite this limited success, we were unable to 
maintain cultures due to cell death. Many cultures were lost early after 
transfection due to mold contamination, a problem which often occurs with long-
term primary cultures. 
It is likely that we were unable to establish an equine 
monocyte/macrophage cell line for a variety of reasons. During other 
experiments done in our laboratory we have had difficulty achieving transient 
expression of transfected genes in primary equine macrophage cultures, which 
was attributed to poor transfection efficiency (see Appendix B). Utilization of 
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nonadherent monocytic cells rather than the adherent macrophage population 
may enhance transformation efficiency since the nonadherent cells are likely to 
be less differentiated. Also, the selection of transformed cells with G418 may 
increase the stability of gene expression. Other viral oncogenes or different 
methods of transformation may also be used to attempt to immortalize primary 
macrophages. 
Table 1. Viability of cells transfected with SVNeo plasmid DNA 
Plasmid Amount® Cell Viability* 
SV3Neo 10 73 
10 6 
20 10 
20 6 
40 10 
40 4 
SVSNeo 10 11 
10 4 
20 10 
20 8 
40 10 
40 5 
Micrograms of plasmid DNA used to transfect cells. 
* Days in culture following transfection that cells remained viable. 
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APPENDIX B. IMPORTANCE OF HOST CELL SPECIHCITY IN EIAV TRANSCRIPTION 
Previously, we described an avirulent isolate of equine infectious anemia 
virus (EIAV), designated MA-1, which was selected for in vitro replication in 
equine dermal (ED) cells [6]. Increased tropism for ED cells was correlated with 
decreased tropism for horse macrophage cultures (HMC). When the nucleotide 
sequence of MA-1 was compared with that of Th-1, the virulent isolate of EIAV 
from which MA-1 was derived, several regions of hypervariability were 
identified in the viral long terminal repeat (LTR), envelope and S3 open reading 
frame [1,5]. To determine if a relationship exists between the hypervariability 
regions of the EIAV promoter and host cell tropism, we decided to functionally 
characterizing these regions of the LTR using transient expression assays in ED 
cells and HMC. 
A variety of LTRCAT expression plasmids were previously constructed 
which contain LTR sequences from the MA-1 and Th-1 isolates of EIAV inserted 
upstream of the reporter gene chloramphenicol acetyl tranferase (CAT) (Figure 
1). For the experiments described below, liposome-mediated transfection was 
used to transfer 10 ^g of each construct into triplicate cultures of ED cells. In an 
attempt to obtain transient gene expression of the LTRCAT constructs in HMC, 
duplicate cultures were transfected with 10 )xg of each construct at various time 
points following culture and using several different methods of transfection 
(Table 1). Since the EIAV LTR is a relatively weak promoter, co-transfection with 
pRS-Etat M, an EIAV Tat expression plasmid was used to increase the sensitivity of 
the assay. 
CAT activity was readily detectable in ED cells co-transfected with LTRCAT 
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CMT TATA 
-J 1 
U3 
—I— 
Afl III 
R U5 
MA-1 
lA Th-1.111xMA-1 
3A Th-1.11xMA-1 
J2 Th-1.152xMA-1 
Figure 1. LTRCAT constructs used to transfect ED cells and HMC 
Table 1. Conditions used for transfection of HMC 
Plasmids Transfection Procedure Days in Culture*" 
MA-1 Ca2P04 precipitation 2 
lA electroporation^ 4 
3 A DEAE dextran 7 
J2 liposome-mediated 
^ Days in culture prior to transfection. 
^ Cells were electroporated using 250 volts and 500 or 
250 volts and 1000 ^F. 
constructs and EIAV Tat (Table 2). In addition, CAT activity was reduced more 
than two-fold in ED cells transfected with 3A, as compared to cells transfected 
with other constructs. However, 3A is identical to MA-1 in the hypervariable 
region [5], which suggests that cell-specific regulation of the LTR involves 
sequences other than those which occur in the hypervariable region. CAT 
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activity in constructs containing Th-1 variant lA sequences was similar to that 
observed with MA-1 construct. Therefore, differences in tropism between MA-1 
and Th-1 in ED cells cannot be attributed solely to differences in the variable 
region of the LTR. Further experiments are needed to determine if nucleotide 
substitutions which occur outside the hypervariable region affect host cell 
specificity. 
Table 2. CAT activity in ED cells'* 
Cells LTRCAT Construct % Conversion^ 
m MA-1 28.0 
lA 26.4 
3A 13.0 
J2 49J 
^ ED cells were transfected with 10 of each plasmid. 
^ The average of triplicate samples. 
No significant CAT activity was detected in HMC, regardless of the method 
of transfection used or the time in culture prior to transfection. It is likely that 
these results are due to poor transfection efficiency of primary macrophages 
since no CAT activity was detected in cells transfected with a plasmid containing 
the CAT gene driven by the SV40 late promoter. In order to functionally 
characterize the variant LTRs in primary HMC, it may be necessary to utilize 
alternative methods of gene expression, such as full length infectious clones. 
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An alternative approach to look at EIAV transcription and cell tropism was 
to compare transcription of MA-1 in cells which differ in permissiveness for 
virus replication in vitro. Previous studies showed that MA-1 replicates to high 
titers in ED cells, but to relatively lower titers in HMC [6]. The relationship 
between EIAV transcription and host cell specificity was examined using the 
reverse transcription-polymerase chain reaction (RT-PCR). HMC and ED cells 
were infected with MA-1, and at 16, 24, 40, 64, and 89 hours following infection 
total cellular RNA was isolated using guanidinium thiocyanate (Stratagene, La 
Jolla, CA). Specific viral mRNA transcripts were reverse transcribed into DNA 
with random hexamer primers, and the subsequent cDNA produced was amplified 
by PGR using splice-specific primers (Figure 2) with the GeneAmp Kit (Perkin 
Elmer-Cetus, Norwalk, CT). EIAV-specific primers were designed based on 
published sequences [48] and previously described splicing patterns 
[2,84,101,113]. Reaction products were electrophoresed in 2% agarose, 
transferred to nylon membranes overnight, and hybridized with probes specific 
for each corresponding amplified sequence. 
There appeared to be no cell-specific differences in the detection of full-
length transcripts, however, genomic RNA which entered the cell during 
infection cannot be distinguished from newly transcribed full-length 
transcripts by the methods used. Cell-specific differences between HMC and ED 
cells were observed in the rate of transcription of specific EIAV mRNA 
transcripts. Singly and multiply spliced transcripts were detected at earlier time 
points following infection in ED cells as compared to HMC (Figure 3). For 
example, singly-spliced transcripts were detected in ED cells at 24 hours post­
infection but remained undetectable in HMC until 40 hours. Also, at 16 hours 
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after infection triple-spliced mRNA was observed in ED cells while this transcript 
was not observed until 24 hours in HMC. Previously, MA-1 virus was found to 
replicate to significantly higher titers in ED cells as compared to HMC [6]. 
Differences in viral permissiveness may reflect differences in the rate of EIAV 
transcription which occurs among ED cells and HMC. 
We previously found that splicing patterns of multiply spliced EIAV 
transcripts in HMC differ from those previously reported [2,84,101,113]. To 
determine if a relationship exists between host cell tropism and splicing 
patterns, EIAV transcripts were amplified from ED cells and HMC using primer 
pair S which was designed to amplify sequences spanning all spliced regions 
(Figure 2). 
S— [2! TatSZEnv Rev Lg 
9 
la lo lb 
C O  
IC 
2a 
3 
g 
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Figure 2. Location of primers used to amplify specific EIAV mRNA by RT-PCR 
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Results showed that alternative splicing patterns differing from those 
previously described had been used to generate multiply spliced EIAV 
transcripts. In addition, splicing patterns varied depending both on the cell type 
infected and hours following infection. Since these transcripts likely encode 
viral regulatory proteins, it may be expected that alterations in splicing patterns 
would affect transcription and translation of viral structural proteins. In 
summary, cell-specific differences were observed in the rate of transcription of 
specific EIAV mRNAs as well as in the post-transcriptional processing required to 
produce multiply spliced transcripts. Both are likely to influence the 
permissiveness for EIAV replication in different cell types. 
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Figure 3. Detection of EIAV mRNA transcripts in HMC and ED cells 
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Figure 4. Ccll-spccific splicing patterns of EIAV 
